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Nos eucariotas, a transcric¸a˜o dos genes pela RNA Polimerase II origina mole´culas
precursoras de RNA mensageiro (pre´-mRNA), sendo necessa´rias va´rias etapas de proces-
samento ate´ a` formac¸a˜o do RNA maduro (mRNA) que e´ transportado para o citoplasma,
onde serve de molde para a s´ıntese proteica.
Adicionalmente, a mesma mole´cula de pre-mRNA pode gerar diversos tipos de mRNA
funcional devido ao splicing alternativo. Este processo consiste na inclusa˜o ou exclusa˜o
de regio˜es do pre´-mRNA e e´ um importante mecanismo responsa´vel pela grande variedade
de prote´ınas nos Eucariotas (Black, 2003). Va´rios estudos baseados em ana´lises de ESTs
(expressed sequence tags) revelaram que mais de 60% dos genes humanos esta˜o sujeitos ao
splicing alternativo, e esse nu´mero aumentou para 80% com o aparecimento dos microar-
rays (Johnson et al., 2003; Kampa et al., 2004). Mais recentemente, as novas tecnologias
de sequenciac¸a˜o de RNA revelaram 92 a 95% dos genes humanos sujeitos ao splicing al-
ternativo (Wang et al., 2008a; Pan et al., 2008).
O splicing do pre´-mRNA esta´ a cargo do spliceosoma, um complexo macromolecular
formado a partir de va´rias pequenas part´ıculas ribonucleoproteicas nucleares (snRNPs)
e outras prote´ınas reguladoras (Jurica and Moore, 2003; Wahl et al., 2009). Atrave´s de
interacc¸o˜es do RNA e prote´ınas do complexo com o pre´-mRNA, os snRNPs medeiam o
reconhecimento e subsequente ligac¸a˜o a`s junc¸o˜es exa˜o-intra˜o (s´ıtio de splicing).
A selecc¸a˜o e identificac¸a˜o entre os diferentes s´ıtios de splicing depende de mu´ltiplas
interacc¸o˜es RNA-RNA e RNA-prote´ına que envolvem a ligac¸a˜o cooperativa de va´rias
prote´ınas reguladoras (reguladores em trans) aos sinais reguladores na˜o codificantes na
sequeˆncia do pre´-mRNA (regulac¸a˜o em cis). Os sinais reguladores incluem sequeˆncias
curtas e muito degeneradas localizadas nos s´ıtios de splicing e outras sequeˆncias regu-
ladoras denominadas de activadores (enhancers) e silenciadores (silencers) localizadas em
exo˜es ou intro˜es. Os reguladores em trans sa˜o designados de factores de splicing e usual-
mente classificadas como activadores ou repressores, dependendo se facilitam ou suprimem
a ligac¸a˜o dos snRNPs aos s´ıtios de splicing.
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O processo de splicing alternativo e´ regulado em resposta a vias de sinalizac¸a˜o, e e´
espec´ıfico a fases de desenvolvimento e tipo de tecido. De acordo com o actual modelo, a
regulac¸a˜o do splicing alternativo resulta de interacc¸o˜es combinato´rias de va´rias prote´ınas
agindo positivamente e negativamente, e deciso˜es de splicing espec´ıficas a um tipo de ce´lula
ou tecido resultam provavelmente de diferenc¸as na concentrac¸a˜o e/ou actividade destas
prote´ınas (Matlin et al., 2005; Shin and Manley, 2004; Singh and Valca´rcel, 2005). Uma
previsa˜o imediata deste modelo e´ que a abundaˆncia relativa das prote´ınas reguladoras de
splicing deve variar de acordo com os tecidos.
Ao longo das u´ltimas de´cadas comec¸aram a ficar dispon´ıveis dados em larga escala
para abordar sistematicamente esta questa˜o, permitindo o desenvolvimento de meta-
ana´lises computacionais. A tecnologia dos microarrays alterou profundamente o modo
de investigac¸a˜o, movendo de uma abordagem gene-a-gene para estudos globais e a` escala
do genoma.
Neste contexto, o presente estudo teve como objectivo gerar previso˜es baseadas em
microarrays para compreensa˜o do co´digo do splicing alternativo que controla e coordena
o transcriptoma.
Para explorar a hipo´tese da expressa˜o espec´ıfica a tecidos das prote´ınas de splicing,
neste trabalho analisamos padro˜es de expressa˜o ge´nica obtidos a partir de estudos de
microarray anteriormente publicados. A ana´lise contemplou as va´rias famı´lias de prote´ınas
hnRNP, SR, cinases-SR, helicases de RNA, prote´ınas snRNP e muitas outras prote´ınas
associadas com o splicing (Barbosa-Morais et al., 2006; Chen et al., 2007).
Em primeiro lugar, o estudo incidiu na alterac¸a˜o da expressa˜o dos factores de splic-
ing durante quatro tipos de diferenciac¸a˜o celular do ratinho: mioge´nese, adipoge´nese,
eritropoiese e espermatoge´nese. Para identificar variac¸o˜es da expressa˜o espec´ıficas ao tipo
celular foi necessa´rio comparar dados de microarray provenientes de diferentes sistemas
biolo´gicos e ensaios experimentais. Para resolver este problema, foi desenvolvida uma nova
abordagem que se baseia em me´todos de regressa˜o (Grosso et al., 2008). A minha ana´lise
revelou diferenc¸as robustas que distinguem um processo de diferenciac¸a˜o dos outros e es-
tas assinaturas de expressa˜o ge´nica inclu´ıam prote´ınas das va´rias famı´lias dos factores de
splicing.
Em seguida, explorei as variac¸o˜es na expressa˜o dos factores de splicing em va´rios teci-
dos humanos, de chimpanze´ e de ratinho. Comparando padro˜es de expressa˜o do ce´rebro,
test´ıculos, corac¸a˜o, f´ıgado e rim, 104 genes apresentaram alterac¸o˜es na expressa˜o espec´ıficas
a tecidos, em pelo menos um organismo. A minha ana´lise revelou que o maior nu´mero
de factores de splicing diferencialmente expressos ocorreu no test´ıculo e no ce´rebro, en-
quanto que o f´ıgado apresentou padro˜es semelhantes ao rim. Curiosamente, os resultados
mostram que os dois tecidos com maior quantidade de splicing alternativo (Yeo et al.,
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2004; Pan et al., 2004; Clark et al., 2007) sa˜o os que apresentam uma maior variac¸a˜o na
expressa˜o de factores de splicing. Assim, os meus resultados mostram que assinaturas de
factores de splicing esta˜o correlacionadas com padro˜es de splicing espec´ıficos de tecidos.
Utilizando PCR quantitativo em tempo real confirmei 75% das previso˜es dos microar-
rays para a miogenese e eritropoiese e 71% para va´rios tecidos. De um modo geral, eu
identifiquei mais de 100 genes que apresentam uma expressa˜o diferencial associada a um
determinado tecido ou processo de diferenciac¸a˜o. Estes resultados mostraram que to-
dos os genes das principais famı´lias de factores de splicing apresentam expressa˜o ge´nica
diferencial, incluindo prote´ınas cinases-SR e prote´ınas dos snRNP.
O processo de splicing alternativo esta´ tambe´m associado a doenc¸as humanas, incluindo
cancro (Wang and Cooper, 2007; Cooper et al., 2009). Sa˜o conhecidas va´rias mutac¸o˜es que
afectam o splicing de oncogenes, genes supressores tumorais e outros genes relevantes para
o cancro (Srebrow and Kornblihtt, 2006; Venables, 2006). Contudo, muitas das anomalias
de splicing identificadas nas ce´lulas tumorais na˜o esta˜o associados com mutac¸o˜es nos genes
afectados. De facto, estudos recentes sugerem que as mudanc¸as na expressa˜o de factores
de splicing podem desempenhar um papel fundamental na perturbac¸a˜o geral do splicing
que ocorre em muitos cancros (Kirschbaum-Slager et al., 2004; Karni et al., 2007; Kim
et al., 2008; Ritchie et al., 2008).
Com o objectivo de pesquisar eventuais associac¸o˜es entre a expressa˜o de factores de
splicing e padro˜es de splicing em cancro, realizei uma meta-ana´lise global que integra dados
em larga escala de experieˆncias de microarrays em va´rios tipos de cancro. A evoluc¸a˜o da
tecnologia dos microarrays tem permitido explorar a expressa˜o ge´nica ao n´ıvel do exa˜o e
estudar variac¸o˜es dos padro˜es de splicing em grande escala (Blencowe, 2006).
Em primeiro lugar, estudei as variac¸o˜es de expressa˜o ge´nica de va´rios factores de splic-
ing em 13 tipos de cancro: bexiga, ce´rebro, mama, co´lon, eso´fago, cabec¸a e pescoc¸o,
rim, f´ıgado, pulma˜o, neuroblastoma, pro´stata, tiro´ide e vulva. Comparando cancro e
correspondentes tecidos normais foram identificadas variac¸o˜es para 192 genes, que codi-
ficam prote´ınas das famı´lias dos factores de splicing snRNPs, hnRNPs, SRS, cinases-SR,
RNA-helicases e outros reguladores de splicing. Os meus resultados tambe´m mostraram
que a maioria dos factores de splicing com variac¸o˜es na expressa˜o eram essencialmente
mais expressos em cancro (sobre-expressa˜o), e de facto foi observado um enriquecimento
de factores de splicing entre todos os genes sobre-expressos. Alguns genes desregulados
apareciam em va´rios cancros, sugerindo que alguns cancros podem apresentar as mesmas
variac¸o˜es de factores de splicing.
Em seguida, seleccionei um conjunto de eventos de splicing desregulados em cancro
atrave´s da aplicac¸a˜o de uma metodologia de ana´lise exaustiva a dados de microarrays de
splicing de estudos anteriores em cancro do co´lon e pulma˜o. Foram encontrados exo˜es con-
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tendo s´ıtios de ligac¸a˜o para SF2/ASF obtidas a partir dados de CLIP-seq (Sanford et al.,
2009) para SF2/ASF, que e´ sobre-expresso em ambos os cancros. Foram tambe´m identifi-
cadas pequenas sequeˆncias enriquecidas associadas com eventos de splicing de cancro que
apresentam alguma semelhanc¸a a s´ıtios de ligac¸a˜o de factores de splicing desregulados em
cancro.
Conclu´ındo, o presente trabalho forneceu contribuic¸o˜es cient´ıficas novas e importantes
para a compreensa˜o do co´digo do splicing alternativo que controla e coordena o transcrip-
toma. Os meus resultados reforc¸am o actual modelo de regulac¸a˜o do splicing alternativo,
que sugere que as diferenc¸as na abundaˆncia relativa ou actividades espec´ıficas de va´rias
prote´ınas influenciam deciso˜es no mecanismo de splicing. Este trabalho alargou a lista
de poss´ıveis reguladores para splicing alternativo associado a` diferenciac¸a˜o celular e ao
cancro, o que desencadeia novas linhas de investigac¸a˜o e validac¸a˜o experimental.
Finalmente, o presente trabalho mostra o poder de utilizar a tecnologia dos microarrays
e abordagens computacionais para gerar previso˜es para uma visa˜o global da regulac¸a˜o do
splicing alternativo.
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The present study aimed to generate microarray-based predictions for understanding
the alternative splicing code that controls and coordinates the transcriptome. To explore
the hypothesis that splicing proteins are expressed in a tissue-specific manner, I anal-
ysed gene expression profiles from previously published microarray studies. The analysis
included members of the hnRNP and SR protein families, SR protein kinases, DEAD-
box RNA helicases, snRNP proteins and several splicing-related proteins (Barbosa-Morais
et al., 2006; Chen et al., 2007). First, I focused on variations of splicing factors dur-
ing four types of murine cell differentiation: myogenesis, adipogenesis, erythropoiesis and
spermatogenesis. To identify cell-type specific variations in splicing factor expression, mi-
croarray data sets derived from different biological systems and experimental assays have
to be compared. To address this issue, I developed a new approach that is based on re-
gression modelling methods (Grosso et al., 2008). My analysis revealed robust differences
that distinguish one differentiation process from the others and these gene expression
signatures included members of several splicing-related protein families. Second, I ex-
plored variations in splicing factor expression across tissues from human, chimpanzee and
mouse. Comparing brain, testis, heart, liver and kidney gene profiles, 104 genes showed
tissue-specific expression variation in at least one organism. My analysis revealed that
the highest number of highly differentially expressed splicing-related genes occurred in
the testis and in the brain, whereas the liver showed higher concordance in expression of
splicing-related genes relative to other tissues, namely the kidney. Interestingly, the results
distinguished the two tissues previously described with highest abundance of alternatively
spliced mRNA isoforms that differ by inclusion or exclusion of an exon (Yeo et al., 2004;
Pan et al., 2004; Clark et al., 2007), as those with a highest variation in splicing factor
expression. Thus, my findings showed that splicing factor signatures correlate with tissue-
specific alternative splicing patterns. By using quantitative real time PCR, I confirmed
75% of microarray predictions for myogenesis and erythropoiesis and 71% for several tis-
sues. Overall I identified over 100 splicing-related genes that are most highly differentially
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expressed in a particular tissue or differentiation process. These results showed that genes
from the main splicing factor families present differential gene expression, including SR
protein kinases and snRNP proteins.
Alternative splicing is associated with several human diseases, including cancer (re-
viewed in Wang and Cooper, 2007; Cooper et al., 2009). Several mutations are known
that affect the splicing of oncogenes, tumour suppressors and other cancer-relevant genes
(Srebrow and Kornblihtt, 2006; Venables, 2006). However, many splicing abnormalities
identified in cancer cells are not associated with mutations in the affected genes. Indeed,
recent studies suggest that changes in splicing factor expression may play a key role in
the general splicing disruption that occurs in many cancers (Kirschbaum-Slager et al.,
2004; Karni et al., 2007; Kim et al., 2008; Ritchie et al., 2008). To investigate whether
misregulation of splicing factor expression correlates with cancer-associated splice vari-
ants, I applied a global meta-analysis that integrates large-scale data from microarray
experiments in several cancer types. Microarray technology evolution allowed to resolve
exon-level gene expression and enabled large-scale profiling of mRNA splicing (reviewed
in Blencowe, 2006). First, I explored gene expression variations of several splicing factors
in 13 cancer types: bladder, brain, breast, colon, esophagus, head and neck, kidney, liver,
lung neuroblastoma, prostate, thyroid and vulva. Comparing the cancer and correspond-
ing normal tissue, I identified misregulation for 192 splicing-related genes encoding the
major splicing protein families (snRNPs, hnRNPs, SRs, SR-kinases, RNA-helicases-like
and other splicing regulators). My results also showed that the majority of differentially
expressed splicing regulators were up-regulated in cancer and in fact, an enrichment of
splicing factors in total overexpressed genes was detected. Some misregulations appear
consistently in several cancer types, suggesting that some cancers can present common
misregulated splicing factors. Afterwards, I collected a high-confidence set of misregu-
lated splicing events in cancer by applying a comprehensive workflow analysis to splicing
microarray data sets from previous studies for colon and lung cancers. I found misspliced
exons containing cis-acting RNA elements obtained from CLIP-seq data (Sanford et al.,
2009) for SF2/ASF, which is overexpressed in both cancers. Enriched motifs were also
identified in the cancer-associated splicing events that resemble binding sites for other
splicing factors found misregulated in cancer.
My work has given important and original scientific contributions for understanding
the alternative splicing code that controls and coordinates the transcriptome. My results
reinforce the current model for alternative splicing regulation, which postulates that dif-
ferences in relative abundances or activities of multiple proteins influence specific splicing
decisions. Furthermore, the large number of splicing-related genes with differential expres-
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sion found in the present study raises the question of which splicing factors can indeed be
responsible for alternative splicing events relevant for cell differentiation and tumorigene-
sis. This work extended the list of putative regulators for differential alternative splicing,
which triggers new lines of research and experimental validation. Finally, this work shows
the power of using microarray technology and computational approaches to generate initial
predictions for a global view of alternative splicing regulation.
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Preface
In this dissertation are described the results of research work developed between 2006 and
2009 under the supervision of Prof. Dr. Maria Carmo-Fonseca from Faculty of Medicine
(Lisbon University - Portugal) and Prof. Dr. Simon Tavare´ from Oncology Department
(Cambridge University - United Kingdom).
The main goal of this work was to explore and combine large scale data from microar-
ray technology in order to understand the splicing code underlying alternative splicing
regulation.
This dissertation is organized in five chapters.
Chapter 1 corresponds to the general introduction of this dissertation. In this chapter
is exposed the pre-mRNA splicing process and the key regulators of this mechanism,
focusing also on alternative splicing. Next, the microarray technology, assays and the
different types of applications are described. Finally, a brief overview of the bioinformatic
tools for large scale approaches is presented.
Chapter 2 presents results from a large-scale computational analysis of mRNA ex-
pression data where splicing-factor expression signatures were identified for differentia-
tion processes and tissues derived from human, chimpanzee and mouse. The original
work described in this chapter has been integrally published in: Grosso AR, Gomes AQ,
Barbosa-Morais NL, Caldeira S, Thorne NP, Grech G, von Lindern M, Carmo-Fonseca M
(2008) Tissue-specific splicing factor gene expression signatures, Nucleic Acids Research.
36(15):4823-32.
Chapter 3 focuses on gene expression variations of splicing factors in cancer. Results
from the analysis of microarray data for several cancer types are presented, showing several
misregulated splicing factors in cancer. This chapter explores also the emerging role of
splicing factors in cancer, which discussion is written as a review article in: Grosso AR,
Martins S, Carmo-Fonseca M. (2008) The emerging role of splicing factors in cancer,
EMBO Rep, 2008 Nov;9(11):1087-93.
Chapter 4 explores splicing misregulation in cancer using splicing sensitive microarrays.
Here, cancer-associated splicing profiles were identified through the use of a comprehensive
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workflow analysis from splicing microarray data. In this chapter cancer-associated splice
variants which appear to be regulated by splicing factors with gene expression affected in
the same cancer are also described.
Chapter 5 comprises an integrative discussion of results and future perspectives, point-
ing out the contribution of microarray technology for understanding alternative splicing
mechanism and regulation.
During my PhD I have collaborated in projects from different research groups of the
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Genomics, 17;10(1):270.
Individual contribution: microarray data analysis
• Correia DV, d’Orey F, Cardoso BA, Lanc¸a T, Grosso AR, Debarros A, Martins LR,
Barata JT, Silva-Santos B (2009). Highly active microbial phosphoantigen induces
rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-
tumor human gammadelta T-Cells, PLoS ONE, 4(5):e5657.
Individual contribution: microarray data analysis
• Mollet IG, Ben-Dov C, Fel´ıcio-Silva D, Grosso AR, Eleute´rio P, Alves R, Staller R,
Silva TS, Carmo-Fonseca M. Unconstrained mining of mRNA and EST databases
reveals increased alternative splicing complexity in the human transcriptome. (sub-
mitted)
Individual contribution: improvement of mysql database performance and develop-
ment of R based tools for ExonMine webserver
• Gomes AQ*, Correia DV*, Grosso AR, Lanc¸a T, Gomes da Silva M and Silva-
Santos B. Identification of molecular markers of leukemia/ lymphoma susceptibility
or resistance to gamma-delta T cell cytotoxicity. (submitted)
Individual contribution: microarray data analysis
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xii
Preface
Individual contribution: Exon-microarray data analysis
• Hallay H, Cardoso J, Grosso AR, Ferreira J, Carmo-Fonseca M. Global Analysis of
splicing in a cellular model of human aging (manuscript in preparation)
Individual contribution: Exon-microarray data analysis
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tive splicing to drug-induced accelerated senescence. (manuscript in preparation)
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• Campinho MA, Pereira J, Grosso AR, Carmo-Fonseca M. ∆spliceMutation: A
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latory motifs (ESR) (manuscript in preparation)
Individual contribution: collaboration for pipeline development based on R language
and packages
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Chapter 1
Introduction
1.1 pre-mRNA splicing
1.1.1 mRNA biogenesis
Gene expression is the process by which information from a gene is used in the synthesis of
a functional product, including the main steps: transcription, several precursor messenger
RNA (pre-mRNA) processing steps (5′ capping, splicing, 3′ end processing and editing),
export of the mature mRNA to the cytoplasm, translation into amino-acid sequence and
post-translational modification (Figure 1.1). This multistep process requires several com-
plex cellular machines responsible for each specific step in this process. Although the
identification of the protein components of each of these cellular machines has been car-
ried out independently, recent findings suggest that each one of these steps regulating gene
expression is physically and functionally connected to the next, as part of a continuous
process (Orphanides and Reinberg, 2002; Kornblihtt et al., 2004).
Messenger ribonucleic acid (mRNA) is the key intermediary in gene expression, which
carries the genetic information transcribed from deoxyribonucleic acid (DNA) and is trans-
lated as a template for polypeptide synthesis. The mRNA is similar to the DNA molecule,
except that: it is single-stranded; the base uracil (U) substitutes the base thymine (T),
and the pentose sugar is a ribose.
Most genes coding for proteins in eukaryotes are transcribed by the RNA polymerase
II transcription machinery, which can be generally divided in three major components:
the 12-subunit polymerase, five general transcription factors (TFIIB, -D, -E, -F and -H)
and the Mediator complex (reviewed in Boeger et al., 2005; Woychik and Hampsey, 2002).
Transcription takes place in three stages: initiation, elongation and termination. Ini-
tiation involves binding of transcription factors and RNA Polymerase II to the promoter,
local melting (separation of the DNA strands), and forming the first phosphodiester bond.
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Figure 1.1: Gene Expression. A contemporary view representing the several steps regulating
gene expression physically and functionally connected: transcription, post-transcriptional modifi-
cation, translation and post-translational modification(Image adapted from Orphanides and Rein-
berg, 2002).
.
During elongation, the RNA polymarease II moves 5′ to 3′ along the gene sequence and ex-
tends the transcript. In termination, the transcript is released from the RNA polymerase
and the polymerase from the DNA template (Orphanides and Reinberg, 2002).
The transcripts initially produced are designated as precursor messenger RNAs (pre-
mRNAs) and undergo several modification steps before transport to the cytoplasm as
functional mRNAs and posterior translation into proteins.
Pre-mRNA processing occurs co-transcriptionally and includes 5′-end capping, splic-
ing, 3′-end processing and editing (Figure 1.1).
The 5′-end capping occurs soon after RNA polymerase II initiates transcription, when
the transcript is about 20-30 nucleotides in length (Proudfoot et al., 2002). This capping
consists of a three-step reaction: first an RNA 5′ triphosphatase hydrolyzes the triphos-
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phate of the first nucleotide to a diphosphate; second a guanylyltransferase catalyzes the
addition of a GMP (guanosine monophosphate) to the first nucleotide of the pre-mRNA
via an unusual 5′-5′ triphosphate linkage; finally a methyltransferase methylates the N7
position of the transferred GMP. This cap serves initially to improve the stability of the
mRNA (protecting the new transcript from attack by nucleases) and later serves as a bind-
ing site for proteins involved in export of the mature mRNA into the cytoplasm (Proudfoot
et al., 2002).
Pre-mRNA splicing is an essential step in the regulation of gene expression due to
the split nature of eukaryotic genes. Most pre-mRNAs are interrupted by long noncoding
sequences named introns that must be removed in order to place the coding sequences,
exons, in a protein-reading frame. The pre-mRNA splicing is described in more detail in
Sections 1.1.2 and 1.1.3.
In the termination step, upon reaching the end of a gene, the newly synthesized RNA
is cleaved and a polyadenosine tail of 200-250 adenosine residues is added to the 3′ end
of the transcript. These 3′ poly(A) tails provide the mRNA with a binding site for a
major class of regulatory factors, the poly(A)-binding proteins (PABPs). These proteins
bind poly(A) using one or more RNA-recognition motifs and have several roles in medi-
ating gene expression. PABPs are necessary for the synthesis of the poly(A) tail in the
nucleus, regulating its ultimate length and stimulating maturation of the mRNA. Associ-
ation with PABP is also a requirement for some mRNAs to be exported from the nucleus.
Finally, PABPs promotes translation initiation and termination, recycling of ribosomes,
and stability of the mRNA in cytoplasm (Mangus et al., 2003).
Besides capping, splicing and 3′-end processing, pre-mRNA undergoes another modi-
cations broadly defined as RNA editing. These modifications of the pre-mRNA can occur
through insertion or deletion of nucleotides or by the substitution of bases. The most
common in mammals are deamination reactions, like the conversion of C to U and of A to
I (inosine, that is equivalent to G for translation process). These modications can affect
both coding and non-coding (namely intronic) sequences and are suggested to regulate
splicing and to have a role in processing and stability of mRNAs (reviewed in Keegan
et al., 2001; Gerber and Keller, 2001).
After pre-mRNA processing, the mature mRNA is exported by factors that bind to
mRNA molecules in the nucleus and direct them into the cytoplasm though interactions
with proteins that line the nuclear pores (reviewed in Reed and Hurt, 2002; Cole and
Scarcelli, 2006).
Translation of mRNA into protein takes place in cytoplasm on large ribonucleoprotein
complexes called ribosomes (reviewed in Ramakrishnan, 2002). The process begins with
the location of the start codon (AUG) by translational initiation factors in conjunction with
3
Introduction
subunits of the ribosome and involves elongation and termination phases (recognition of
stop codons UAA, UAG or UGA) (reviewed in Dever, 2002; Sonenberg and Hinnebusch,
2009). Finally, the nascent polypeptide undergoes folding and often post-translational
modications to generate the final active protein (reviewed in Daggett and Fersht, 2003).
1.1.2 Spliceosome and splicing signals
Pre-mRNA splicing is carried out by the spliceosome, a macromolecular complex formed
from several small nuclear ribonucleoprotein particles (snRNPs) and numerous non-snRNP
splicing factors (reviewed in Jurica and Moore, 2003; Wahl et al., 2009) (Figure 1.2).
Initial mass spectrometric studies of spliceosomal complexes indicated that between 150
and 300 distinct proteins copurify with spliceosomes (Zhou et al., 2002; Rappsilber et al.,
2002). More recently, studies purifying spliceosomes at more defined stages of assembly and
function indicated that the total number of spliceosome-associated factors is approximately
170 (reviewed in Wahl et al., 2009).
The splicing process requires several specific RNA-RNA, RNA-protein and protein-
protein interactions to recognise the exon-intron junctions and remove the introns. Some
of these interactions are mediated by several cis-acting elements, RNA sequence signals,
that distinguish exons from introns, direct the spliceosome to the correct nucleotides for
exon joining and intron removal, and serve as binding sites for auxiliary factors (trans-
acting elements).
snRNPs
Each snRNP particle consists of stable small nuclear RNA (snRNA) bound by a core ring
of seven different Sm or Sm-like proteins, and several particle-specific proteins (reviewed
in Jurica and Moore, 2003) (Figure 1.2).
The major spliceosomal snRNPs U1, U2, U4, U5 and U6 are responsible for splicing the
vast majority of pre-mRNA introns (so-called U2-type introns). A group of less abundant
snRNPs, U11, U12, U4atac and U6atac, together with U5, are subunits of the so-called
minor spliceosome. The minor splicing system targets a rare class of introns (U12-type
or minor-class introns) (reviewed in Patel and Steitz, 2003). The snRNPs carry out a
number of essential functions during splicing. Via the interactions of their RNA and
protein components with the pre-mRNA, they mediate the recognition and subsequent
pairing of the 5′ and 3′ boundaries of the intron.
The core signals that define the intron correspond to four poorly conserved sequences:
the exon-intron junctions at the 5′ and 3′ ends of the intron (designated as 5′ and 3′ splice
site, respectively), the polypyrimidine tract (polyimmediately preceding 3′ splice site (a
stretch of 15-25 nucleotides enriched with pyrimidine residues), and the branch point
4
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Figure 1.2: Compositional dynamics of human spliceosomal complexes formed by
snRNPs during splicing process (Image from Wahl et al., 2009).
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Figure 1.3: Consensus sequences of major-class and minor-class introns. The size of a
nucleotide at a given position is proportional to the frequency of that nucleotide at that position.
The positions that are thought to be involved in intronrecognition are shown in black; other
positions are shown in blue. Frequencies were derived from a set of U12-type introns from various
plant and animal species and from a set of mammalian U2-type introns (Image from Patel and
Steitz, 2003).
sequence (which includes an adenosine residue). During the splicing reaction snRNAs
interact by base paring with the splice sites and branch point regions (explained in detail
below). Thus, different sequence elements are found in U2- and U12-type introns (Figure
1.3).
The U2-type introns in higher eukaryotes have the highly conserved signals 5′-GU...
A ... Y(10-20) .... AG-3′ for 5′ splice site, branch point, polypyrimidine tract and 3′
splice site, respectively (Figure 1.3). However, these longer consensus sequences can be
extended to R/GURAGU for 5′ splice site (/ denotes the exon-junction), YNYURAYY for
the branck poinst and YAG for 3′ splice site. The U12-type introns lack the polypyrim-
idine tract upstream the 3′ splice site and contain highly conserved splicing signals: 5′-
RUAUCCUUU ... UCCUAAC ... YAS-3′ for 5 splice site, branch point and 3 splice,
respectively. The introns were initially named AT-AC due to the first discoveries, how-
ever recent findings revealed that most U12-type introns have GT-AG boundary sequences
(reviewed in Patel and Steitz, 2003).
SR, hnRNPs and other splicing-related genes
To compensate for the short and poorly conserved nature of splice-site sequences in higher
eukaryotes, recognition of higher eukaryotic introns often relies on other cis-acting regu-
latory elements located in exons and introns that act as splicing enhancers and silencers
(Izquierdo and Valca´rcel, 2006). These splicing regulatory elements (SREs) are bind-
ing sites for additional splicing factors that can enhance or prevent the association of the
snRNPs to the adjacent splice sites. Indeed, most of the functionally important RNA-RNA
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interactions formed within the spliceosome are weak and generally require the assistance
of proteins to enhance their stability.
One class of factors recognizing enhancer sequences are the the Serine/Arginine-rich
(SR) proteins, which contain one or more domains rich in serine and arginine residues
(the RS domain) and RNA-binding domains or RNA recognition motifs (RRM). Some
examples of classical SR proteins (and respective human official gene symbol (defined by
HUGO Gene Nomenclature Committee - HGNC) are: ASF/SF2 (SFRS1), SC35 (SFRS2),
SRp46 (SFRS2B), SRp20 (SFRS3), SRp75 (SFRS4), SRp40 (SFRS5), SRp55 (SFRS6),
9G8 (SFRS7) (reviewed in Long and Caceres, 2009).
Some additional splicing factors also contain RS domains but are not considered as clas-
sical SR proteins, referred as SR-related proteins. Among the most important SR-related
proteins is the U2 snRNP auxiliary factor (U2AF) which in mammals is composed of a 35
and a 65 kDa subunit, named U2AF35 (U2AF2) and U2AF65 (U2AF1) respectively. These
two subunits also contain RRM domains and bind to the polypyrimidine tract (U2AF65)
and 3′ splice site (U2AF35), promoting the stable binding of U2 snRNP to the branch site.
Examples of other SR-related proteins are: U1-70K (SNRP70), SRp30c (SFRS9), hTra2β
(SFRS10), hTra2α (TRA2A), p54 (SFRS11), SRrp86 or SRrp508 (SFRS12), SRm160
(SRRM1), SRm300 (SRRM2) (reviewed in Long and Caceres, 2009).
SR proteins play diverse roles in many aspects of mRNA processing including splic-
ing, export, and translation (reviewed in Graveley, 2000). The sub-cellular localization
and activity of SR proteins is modulated by extensively phosphorylation of their RS do-
mains. Several protein kinase families have been shown to phosphorylate the RS domain
of SR proteins, including the SRPK (SR protein kinase) family, the Clk/Sty family and
topoisomerase (reviewed in Stamm, 2008; Long and Caceres, 2009).
Other non-snRNP splicing factors that contain also RRM domains are the heterogenous
nuclear ribonucleoproteins (hnRNPs). hnRNPs can repress splicing by directly antagoniz-
ing the recognition of splice sites, or can interfere with the binding of proteins bound to
enhancers, like SR proteins. There are several hnRNPs and more than 20 of them have
been characterized and given alphabetical names based on size from hnRNP A1 to hnRNP
U. They have been implicated in a variety of biological processes including telomere biogen-
esis, translation, RNA stability and splicing (reviewed in Martinez-Contreras et al., 2007).
A function in splicing has been documented or proposed for more than half of the major
hnRNPs: A1 (HNRNPA1), A2 (HNRPA2B1), E1 and 2 (PCBP1 and PCBP2), C (HN-
RNPC), F (HNRNPF), H (HNRNPH1), H’ (HNRNPH2), 2H9 (HNRNPH3), G (RBMX),
PTB (PTBP1), nPTB (PTBP2), K (HNRNPK), L (HNRNPL), M (HNRNPM), Q (SYN-
CRIP), R (HNRNPR) (Venables et al., 2008). Other hnRNP proteins like N, S and T
remain poorly characterized and there is no evidence that the hnRNP proteins A0, A3,
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A/B, D, DL and U play a role in splicing (reviewed in Martinez-Contreras et al., 2007).
One more class of proteins essential for splicing reaction are the proteins from RNA-
helicases superfamily, namely DEAD and DEAH box families. The family names de-
rived from the conserved motif II with the four amino-acids Aspartic acid-Glutamic acid-
Alanine-Aspartic acid (DEAD in one-letter code) Aspartic acid-Glutamic acid-Alanine-
Histidine (DEAH), being also known as DExH/D (where x can be any amino acid) (re-
viewed in Rocak and Linder, 2004). These proteins are associated with all processes
involving RNA molecules, including transcription, splicing, editing, ribosome biogenesis,
RNA export, translation, etc. In pre-mRNA splicing DEAD-box proteins are required for
establishment of a functional spliceosome, whereas DEAH-box proteins are (indirectly)
required for the trans-esterication reactions, the release of the mRNA, and the recycling
of the spliceosome components. Examples of DExH/D proteins acting in splicing are
DDX3Y, DDX23 (orthologous of yeast Prp28 protein), DDX46 (orthologous of yeast Prp5
protein), UAP56 (BAT1), DDX5, p75, Prp2, Prp16, Prp22, Prp43, DDX42 (reviewed in
Linder, 2006).
1.1.3 Spliceosome assembly
Assembly begins with the binding of the U1 snRNP through base-pairing interactions of
the 5′-end of the U1 snRNA to the 5′ splice site (Figure 1.4). This interaction in higher
eukaryotes is stabilized by members of the SR proteins. Early assembly step also require
the binding of SF1 (Splicing Factor 1) protein and the U2AF subunits to the branch point
and the polypyrimidine tract, respectively. SF1 interacts with U2AF65 and the other
subunit of the U2AF heterodimer, U2AF35, binds AG dinucleotide of the 3′ splice site.
Together, these molecular interactions yield the spliceosomal E complex and play crucial
roles in the initial recognition of the 5′ and 3′ splice sites of an intron and brings the splice
sites that are to be cleaved and joined into juxtaposition.
After the formation of the spliceosomal E complex, the U2 snRNA engages in ATP-
dependent manner and in a base-pairing interaction with the brach point, leading to the
formation of the A complex. This base-pairing interaction is stabilized by heteromeric
protein complexes of the U2 snRNP (namely SF3a and SF3b) and also by the U2AF65
protein. Association of U2 leads to the displacement of SF1 from the branch point.
After A complex formation, the U4/U6 and U5 snRNPs are recruited as a preassembled
U4/U6.U5 tri-snRNP, forming the B complex (or B1). Although all snRNPs are present in
the B complex, it is still catalytically inactive and requires major conformational and com-
positional rearrangements (catalytic activation) in order to become competent to facilitate
the first out of two trans-esterification reactions involved in splicing. During spliceosome
activation, U1 and U4 are destabilized or released, giving rise to the activated spliceosome
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Figure 1.4: Spliceosome Assembly. Exons are represented by thick and introns by thin lines;
protein particles (U snRNPs, U2AF and SF1) are represented by round shapes; snRNAs are
depicted by the lines accompanying snRNPs; splice sites and branch point (A) are indicated (Image
modified from Gama-Carvalho, 2002).
.
(the B2 or C complex). The activated spliceosome then undergoes the first catalytic step
of splicing, generating the C complex. The 3′-5′-phosphodiester bond at the 5′ splice site
is attacked by the 2′-hidroxyl group of the conserved intronic adenosine at the branch site.
A 2′-5′ phosphodiester bond is formed, generating a intron lariat and a free 5′ exon, with
a 3′-hidroxyl group. Then the second trans-esterification occurs, where the 3′-hidroxyl
group of the 5′ exon attacks the phosphodiester bond at the 3′ splice site, releasing the
intron lariat (to be degraded) and ligating the exons. After the second catalytic step, the
spliceosome dissociates, releasing the mRNA and the U2, U5, U6 snRNPs to be recycled
for additional rounds of splicing (reviewed in Wahl et al., 2009).
Assembly of the minor spliceosome is similar to that of the major spliceosome, with
the U11, U12 and U4atac/U6atac being functionally similar to the U1, U2 and U4/U6,
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respcetively. The major difference occurs at the earliest assembly step in which the U11
and U12 snRNPs form a highly stable di-snRNP that binds cooperatively to the 5 splice
site and branch point, which is equivalent to the A complex of the major spliceosome
(reviewed in Patel and Steitz, 2003).
1.1.4 Alternative splicing
Splicing is usually constitutive, which means that all exons are joined together in the order
in which they occur in the pre-mRNA. In many genes, however, alternative splicing has
also been observed, in which the exons may be combined in some other way (Figure 1.5).
For example, some exon or exons may be skipped, being removed similarly to introns.
However, the primary order of the exons is not altered in alternative splicing. Thus
alternative splicing makes it possible for a single gene to produce more than one messenger
RNA molecule, so-called isoforms.
Transcripts from a gene can undergo many different patterns of alternative splicing
(Figure 1.5): transcriptional initiation at different promoters generates alternative first ex-
ons that can be joined to a common exon; alternative terminal with alternative polyadeny-
lation sites can be joined to a common upstream exon; use of alternative 5′ or 3′ splice
sites, exons can be extended or shortened in length; inclusion and skipping of cassette
exon, inserting or deleting a portion of internal sequence; mutually exclusive splicing of
cassette exons, where one exon or the other is included (but not both); intron retention
where the excision of an intron is suppressed. Many genes show multiple positions of
alternative splicing, creating complex combinations of exons and alternative segments and
consequently different protein coding sequences. In addition, alternative splicing can medi-
ate the repression of gene expression by stimulating the formation of transcripts subject to
nonsense-mediate mRNA decay (mRNA degradation) (reviewed in Lejeune and Maquat,
2005).
Several studies based on large-scale expressed sequence tag (EST) analysis estimated
that >60% of human genes undergo alternative splicing, and this number more recently
increased to >80% when microarray data became available (Black, 2003; Matlin et al.,
2005). More recently, high-throughput sequencing technologies are revealing that 92-94%
of human genes undergo alternative splicing (Wang et al., 2008b; Sultan et al., 2008; Pan
et al., 2008).
Alternative splicing relies on the same core signal sequences and regulatory sequence
elements (SREs) as constitutive splicing. Indeed, alternative splicing patterns are usually
determined by the presence of SREs in the regulated exon and its flanking introns. These
SREs can be intronic or exonic splicing silencer elements (ISS or ESS) and intronic or
exonic splicing enhancer elements (ISE or ESE). Enhancer elements promote the inclusion
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Figure 1.5: Patterns of alternative splicing. Constitutive exons are shown as blue boxes,
whereas the remaining colors represent the different alternative patterns. The two splicing patterns
for each case are represented by the lines above and bellow (Image from Li et al., 2007).
.
of an exon, and silencers promote its skipping or exclusion from the final mRNA. Many
of these elements are bound by known RNA-binding proteins (RBPs), such as SR and
hnRNPs. hnRNPs typically bind to ESSs and ISSs, whereas SR proteins usually bind to
ESEs and ISEs (Figure 1.6)
Many more sequence elements have been identified, but their protein mediators are un-
known. Most alternative exons are controlled by the balance of multiple splicing enhancer
and silencer elements (reviewed in Sharma and Black, 2006).
Investigations into individual splicing events and, more recently, combined microarray
and computational analyses have identified subsets of commonly regulated splicing events
that share cis-acting elements associated only with alternative splicing. These elements
are bound by RNA-binding proteins that are not generally associated with the spliceo-
11
Introduction
Figure 1.6: Splicing Signals. Cis-acting elements required for exon-intron recognition and
splicing regulation (Image from Wang and Burge, 2008).
.
some, such as FOX 1 and 2 proteins (A2BP1, RBM9), CUG-binding proteins (CUG-BP
also known as eTR-3-like or CELF proteins) (CUGBP1, CUGBP2, BRUNOL4), MBNL
(MBNL), Nova proteins (NOVA1, NOVA2) NOVA and TIA proteins (TIA1, TIAR). Reg-
ulation of alternative splicing in vertebrates involves a dynamic interplay of antagonistic
regulatory factors; for example, between the SR and hnRNP protein families, and be-
tween pairs of proteins including Nova-PTB, CELF-PTB, CELF-MBNL, TIA-PTB, and
PTB-FOX (reviewed in Wang and Cooper, 2007).
Moreover, many elements are not strict silencers or enhancers, rather the position of
an element relative to an alternative exon can determine whether it acts positively or
negatively, namely Nova (Ule et al., 2006) and FOX2 proteins (Yeo et al., 2009). The
authors suggested an RNA map for Nova and FOX2 proteins: binding sites located in the
alternative exon (only for Nova) and upstream intron work as splicing silencers leading to
exon exclusion, whereas sites in downstream intron act as splicing enchancers promoting
exon inclusion.
1.2 Microarray technology
A microarray, in general, corresponds to a glass or polymer slide, onto which pre-defined
sequences of DNA are attached at fixed locations. The purpose of a microarray is to detect
the abundance of labelled nucleic acids in a biological sample, which will hybridize to the
pre-defined sequences of DNA and measured via the label. Since thousands of different
DNA molecules may be bound to a microarray it is possible to measure the abundance
of many features simultaneously. There are several microarray platforms that differ in
fabrication, sample preparation, experimental design and the methods for data analysis.
DNA microarrays can be used to measure changes in gene expression levels, to detect
12
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single nucleotide polymorphisms (SNPs), alternative splicing changes, etc.
1.2.1 Microarray fabrication
The use of a collection of distinct DNAs in arrays for expression profiling was first described
in 1987 and these early arrays were made by spotting complementary DNA onto filter paper
with a pin-spotting device (Kulesh et al., 1987). The miniaturized microarrays appeared
in 1995 (Schena et al., 1995) and the commercialization of microarrays was started in 1996
by Affymetrix.
Nowadays, there are two main technologies for making microarrays: robotic spotting
and in-situ synthesis.
The spotted DNA probes can be cDNA or DNA oligonucleotides presynthesised. The
cDNA is a single-stranded DNA synthesized from mature (fully spliced) mRNA using the
enzyme reverse transcriptase. The attachment chemistry can be covalent or non-covalent.
In the first case, a primary aliphatic amine group (NH2) previously added to the DNA
probe, bounds to the linkers on the glass. In the non-covalent attachment, the bonding
is made via electrostatic attraction between the phosphate backbone of the DNA probe
and the NH2 attached to the surface of the glass. The spotting robot itself consists of
one or a series of pins arranged as a grid (pin-group) held in a cassette. The pins collect
the DNA probes and spot them onto a number of different arrays. After spotting, the
pins are washed and new DNA probes are collected to be printed. In the end, the surface
of the array can be fixed so that no further DNA can attach to it (Stekel, 2003). This
spotting technology is used most by the research laboratories that produce their own
microarrays. It is the least expensive technology and only requires the spotting robot.
Also, many researchers do not work with model organisms (human, mouse, chicken, yeast,
etc.) and this type of microarrays allow any type of cDNA, obtained from clone libraries
of non-model organisms to be printed on an array.
The other types of microarray platforms are in-situ synthesised oligonucleotide mi-
croarrays. For this type of technology the oligos are built up base-by-base on the surface
of the array. This takes place by several rounds of synthesis where a covalent reaction
occurs between the last added nucleotide and the next one. Each nucleotide added to the
oligonucleotide on the glass has a protective group on its terminal position to prevent the
addition of more that one base during each round of synthesis. The protective group is
then converted to a hydroxyl group before the next round of synthesis. There are different
methods for deprotection: photodeprotection and chemical deprotection with synthesis
via inkjet technology.
The photodeprotection, also called photolitography, is the basis of the Affymetrix
GeneChips. This technique uses light to unprotect the protective group to which further
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nucleotides can be added. The light is directed to appropriate features using masks that
allow light to pass to some areas of the array but not to others. Each round of synthesis
requires a different mask. The mask set is expensive to produce, but once made, it
is straightforward to produce a large number of identical arrays. Thus, the Affymetrix
technology is mostly used to make large numbers of standard arrays for research in model
organisms.
The other type of photodeprotection similar to that described above, directs light via
micromirror arrays. This is the method used by Nimblegen and Febit technologies.
The inkjet technology uses chemical deprotection to synthesise the oligonuclotides. At
each step, the appropriate nucleotide is fired onto each spot of the array. This process
is computer controlled, so any oligonucleotides can be synthesised on the array simply
by specifying the sequences in the computer file. Although, being highly flexible, this
technology is less efficient for making large numbers of identical arrays (Stekel, 2003).
This is the technology used by Rosetta, Agilent and Oxford Gene Technology.
A different approach to the conventional high-density microarrays is the bead array
technology used by Illumina. The beadarrays are based on 3-micro silica beads that self
assemble in microwells on either two substrates: fiber optic bundles or planar silica slides.
The beads are randomly assembled on one of these two substrates and identified using
decoding hybridizations. Each bead pool is covered with hundreds of thousands of copies
of a specific oligonucleotide that act as the capture sequences in one of Illumina’s assays.
Once a bead pool is made, it is relatively straightforward to assemble and decode large
numbers of arrays containing ∼50000 beads. Because individual arrays are only ∼1.4
mm in diameter, they can easily be arranged into a 96-array matrix, designed for parallel
analysis of samples in standard microtiter plates (Gunderson et al., 2004).
1.2.2 Microarray assays
Microarray assays basically consist of the hybridization of nucleic acids (DNA or RNA)
extracted from the tissue or cells of interest with the DNA probes on the microarray. The
type of extracted sample will depend on the final goal: comparative genomic hybridization
or SNPs require DNA, whereas gene expression profiling and alternative splicing studies
require RNA. In the case of RNA extraction, this is afterwards converted into cDNA
using the enzyme reverse transcriptase. Then, the DNA/cDNA sample is labelled with
fluorescent dyes and hybridised to the microarray. After hybridization and washing, the
microarray is excited by a laser and scanned at wavelengths suitable for the detection of
the fluorescence intensities.
The procedures for some of these steps depend on the technology used: single or two-
channel microarrays.
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Figure 1.7: Simplified scheme of the assay steps for two-channel (glass slide) and
single-channel (Affymetrix) microarray platforms. Figure from Staal et al. (2003).
15
Introduction
The Affymetrix GeneChip is an example of gene expression profiling in a single-channel
platform (Figure 1.7). In this assay the cDNA is converted to complementary RNA and
labelled with Biotin-ddUTP. Then, the sample is hybridized into the GeneChip and the
microarray is scanned. The GeneChip contains 11 to 20 probe pairs for each gene. Each
probe pair has perfect-match (PM) probes to specifically hybridize with the transcripts
from the intended gene, and paired mismatch (MM) probes for measuring non-specific
hybridization. The idea is that the final expression value is given by the difference be-
tween the PM and MM signals and the average of the probe pairs for the same gene.
However, in practice the MM probes often cross hybridise with signal from other genes
and sophisticated statistics are needed to combine PM and MM data for a given gene.
The other type of microarrays are the two-channel platforms (Figure 1.7), where two
samples are labelled with different dyes and competitively hybridised to the same array.
The fluorescence emitted by the two dyes is detected by the microarray scanner and
reflects the relative amount of the two target samples hybridised to each probe. The
commonly used dyes Cy3 and Cy5 emit fluorescence in wavelengths 510-550nm and 630-
660nm respectively. The scanner excites both dyes and detects the emission for each of
the red (Cy5) and green (Cy3) channels.
In two-channel platforms, the final expression value is generally given by the compar-
ison between the amount of fluorescence emitted by the two dyes.
One important requirement in the microarray assay is the replication of experiments.
There are two main types of replicates: biological replicates and technical replicates. Bio-
logical replicates are arrays that use biological samples from different individual organisms,
pools of organisms or flasks of cells, but yet compare the same treatments. This type of
replicate allows the assessment of the natural variability of the system. Technical repli-
cates provide information on the differences between samples from the point at which
an individual sample was processed and separated independently. Using an experimental
design which uses both types of replication enables us to estimate both the biological
variance and the noise/error due to the technical differences in array processing (Causton
et al., 2003).
The two-channel platforms typically involve a specific type of technical replication,
designated as a dye-swap. These are replicate arrays with the same samples hybridised
but swapped fluorescent labelling. For example, sample A is labelled with Cy3 and sample
B with Cy5 in the first array, but in the second array the sample A is labelled with Cy5
and sample B with Cy3. Dye swaps are used to estimate technical dye bias in some genes,
because the two fluorescent dyes may be differentially incorporated into DNA and they
emit fluorescence in different wavelengths.
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1.2.3 Microarray applications
Microarrays applications have evolved and transcended the initial goal of gene expression
profile. Microarray can be used for assessing single nucleotide polymorphisms (SNPs),
copy number variation, interactions between proteins and DNA or RNA, methylation
state, alternative splicing changes, etc (Bier et al., 2008).
In a gene expression profiling experiment the abundance levels of thousands of genes
may be simultaneously monitored to study the effects on gene expression of certain treat-
ments, diseases, developmental stages, presence of pathogens or other organisms. Nowa-
days, the expression of approximately 29000 genes can be measured simultaneously using
microarrays with probes matching only the 3′ end of each gene or using probes spread
across the full length of the gene (Robinson and Speed, 2007). The expression of several
non-coding RNAs (microRNAs and small nuclear RNAs) can also be detected using spe-
cific microarrays. Non-coding RNAs are emerging as a major component of the regulatory
circuitry that underlies the development and physiology of complex organisms (Li and
Ruan, 2009).
Microarrays technology development have been also extremely useful for SNPs geno-
typing by allele-specific hybridization to oligonucleotides probes, allowing the detection of
approximately 1 million SNPs in a single experiment (Syva¨nen, 2005).
Different microarray technologies have been used for genome-wide copy number varia-
tion detection: SNPs genotyping microarrays; comparative genomic hybridization (CGH);
tiling microarrays (Carter, 2007).
Comparative Genomic Hybridization measures DNA copy number differences between
a test and reference, allowing the detection of loss, gain and amplification of the copy
number at the levels of chromosomes (Carter, 2007).
Tiling or high-density oligonucleotide microarrays cover the entire genome with oligonu-
cleotide probes overlapping with some base-pairs shift. Potential uses for such whole-
genome arrays include empirical annotation of the transcriptome, interactions between
proteins and DNA or RNA by chromatin-immunoprecipitation-chip, analysis of alterna-
tive splicing, characterization of the methylome (the methylation state of the genome),
SNPs discovery and genotyping and genome resequencing (Mockler et al., 2005).
Microarray-based methods have also been used for identification of interactions be-
tween proteins and DNA or RNA. Sequences bound to a specific protein can be isolated
by chromatin immunoprecipitation (ChIP) or RNA immunoprecipitation (RIP) and these
fragments can be then hybridized to tiling microarrays (ChIP-chip or RIP-chip) allowing
the determination of protein binding site occupancy. For example, transcription factor
binding sites throughout the genome can be identified using ChiP-chip assays. Using the
same technique for other proteins allow the identification of promoter regions, enhancers,
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Figure 1.8: Splicing-sensitive microarrays. The scheme shows the probes (green) distribution
across exons according to the main two types of splicing-sensitive microarrays: exon and exon-
junction centric platforms (Image from McKee and Silver, 2007).
repressors and silencing elements, etc (Durand-Dubief and Ekwall, 2009). RIP-chip has
been applied to identify relationships between transcripts and regulatory RNA-binding
proteins, namely splicing factors (Gama-Carvalho et al., 2006).
Splicing-sensitive microarrays were also developed for large-scale identification of splic-
ing differences between two RNA populations. These microarrays typically contain spotted
oligonucleotide probes that are complementary to individual exons and/or exon-exon junc-
tions for thousands of genes. Splicing microarray reliability can be improved by higher
coverage using both exon probes and exon-junction probes (reviewed in Wang and Cooper,
2007). Several splicing microarray platforms were developed consisting essentially in two
types of approaches exon and exon-junction centric platforms (Figure 1.8). The two ap-
proaches present distinct advantages in their ability to measure transcript structure due the
location of the probes. The exon-centric platforms are more appropriate to identify novel
splicing events since probes are designed for well annotated and predicted exons, whereas
with exon-junction platforms transcript architecture directly targeting pre-determined ar-
rangements of exons can be assessed (reviewed in McKee and Silver, 2007).
In addition, several studies have combined the use of different microarray types to
answer more complex questions, namely correlation between gene expression and copy
number variations (Stransky et al., 2006), gene expression profile and methylation (Mart´ın-
Subero et al., 2009), etc.
The commercially available microarray platforms present also a broad range of genomes
for animal (human, mouse, rat, pig, bovine, canine, chicken, Rhesus Macaque, Xenopus
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tropicalis, Xenopus laevis, Zebrafish, Drosophila, etc.), plants (Arabidopsis, Barley, Cit-
rus, Cotton genomes Array, Maize, Medicago, rice, Soybean, Sugar Cane, tomato, grape,
Wheat, etc.), fungi (Yeast - Saccharomyces cerevisiae) and bacteria (Escherichia coli,
Pseudomonas aeruginosa, Staphylococcus aureus).
1.2.4 Microarray data analysis
The enormous volume of data generated by microarray technology, associated with the
need to properly handle, analyse, interpret and make use of the data, has been a challenge
to many researchers in statistics, computational sciences and biology. As a consequence,
a great diversity of software has been developed and several statistical methods have
been proposed to analyse this type of data. There are several types of programs based
on different programming languages and also some web-based systems: AFM (Breitkreutz
et al., 2001), Babelomics (Al-Shahrour et al., 2006), GEPAS (Montaner et al., 2006), dChip
(Li and Wong, 2001), GenePattern (Reich et al., 2006), R and BioConductor systems (R
Development Core Team, 2009; Gentleman et al., 2004).
Microarray assays are complex experiments with many steps requiring the use of bioin-
formatics tools. In a broad way these steps are: image analysis; data pre-processing and
normalization; statistical analysis; database annotation.
Data Pre-Processing and Normalization
Data preprocessing and normalization programs perform raw data merging, format con-
version, quality assessment and data normalization before higher level analysis.
After microarray scanning, microarray data analysis begins with image processing.
Data extraction from images involves several steps: aligning and overlaying the red and
green images; identification of the arrayed features; detection of saturated spots; deter-
mination of appropriate number of pixels for a spot; etc. Image processing is a critical
step as this primary data collected from each experiment will be the starting point for all
downstream analysis.
After the image processing we obtain the specific hybridization intensity for each probe
(foreground) and the intensity of non-specific hybridisation (background). Background
correction is based on the premise that background estimates represent the non-specific
hybridisation of labelled target to the glass and also some natural fluorescence of the glass
slide itself. Thus, each probe intensity should be corrected for the background and there
are several background correction methods (Stekel, 2003).
Microarray data is usually transformed from the raw intensities into log-intensities.
The are several reasons for this transformation but the main purpose is to make the data
and the model error terms closer to a normal distribution (i.e. to make the distribution of
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the data more symmetrical); to reduce the influence of outliers, especially when they are
at one end of the distribution and to make effects that are multiplicative on the raw scale
additive on a transformed scale. The ratio of the intensities between two sample types
(or red and green channels in two-colour microarrays) is transformed into the difference
between the logs of the intensities of both samples. It is common to use logarithm to base
2. Therefore, a log-ratio of 0 corresponds to a gene with no expression change, while +1
and -1 will correspond to a 2-fold up-regulated and down- regulated genes respectively
(Stekel, 2003).
Finally, the microarray data should be normalized to adjust for effects which arise from
variation in the microarray technology rather than from biological differences between
the RNA samples or between the printed probes (Smyth and Speed, 2003). Microarray
normalization can be split in two phases: normalization within and between-arrays. The
normalization within-arrays corrects spatial effects (heterogeneity in intensities through
the microarray) and dye bias in two-colour microarrays. The dye bias corresponds to a
difference in the red and green probe intensities (two different fluorescent dyes are used to
quantify the samples and their intensity is measured at different wavelengths) that is not
the result of a biological difference in gene expression. The normalization between-arrays
corrects expression intensities so that the intensities or log-ratios have similar distributions
across a series of arrays and thus making it possible to compare samples hybridized in
different slides (Smyth and Speed, 2003).
Class Comparison and Discovery
One of the most important goals in microarray studies is to compare pre-specified classes
(or samples) and identify genes that are differentially expressed between them. Class
comparison methods are supervised in the sense that they utilize the information of which
specimens belong to which classes. This is in contrast to methods such as cluster analysis
for class discovery which do not utilize any information about class membership (Stekel,
2003).
In class comparison, the identification of differentially expressed genes can be consid-
ered in two stages. First it is necessary to select a statistic which will rank the genes in
order of evidence for differential expression. Then, a critical-value for the ranking statistic
is chosen above which any value is considered to be significant. The ranking step is more
important because in many microarray studies the aim is to identify a number of candi-
date genes for confirmation and further study. Since often only a limited number of genes
can be followed up, it is sometimes more important to identify the most likely candidates
than to select a large list where most genes will not be a focus. The statistics used can
be the classical t-test and use the p-value for selecting the cut-off. Another approach was
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described by Smyth (2004), where linear model and empirical Bayes methods are used to
identify differentially expressed genes.
A known problem when performing statistical tests on many genes in parallel is the
multiplicity of p-values. By the general definition, p is the probability of observing data
as extreme as yours under the assumption that the null hypothesis is true and it also
represents the probability of a false positive. So, a gene with a p-value of 0.01 will have
1% of probability of being a false positive. Although 1% is acceptable for one test, when
applying several tests on the same dataset this 1% can result in a large number of false
positives. Microarrays today typically have close to 20000 genes and applying the rule
described above one would expect to find 200 false positives by chance. This is a statistical
problem caused by the analysis of a large number of genes. There are several methods to
correct this artifact: estimated false positive rate; Bonferroni correction; Benjamini and
Hochberg method (Benjamini and Hochberg, 1995); etc.
The goal of class discovery methods is to create classes of specimens for which gene
expression is different. These methods can be used to identify groups of specimens and
then arrange the groups so that the closest groups are adjacent. There are three ways to
group microarray data: analyse the genes, analyse the samples, or both. In the first case,
the aim is to find the groups or sets of genes with similar expression across samples. In the
case of grouping samples, each sample profile will be measured using the expression values
of the genes in that specific sample. Although these two analyses are very different and
used to achieve different results, from the perspective of data analysis methods they are
essentially the same. The only important difference lies in the relative number of samples
and genes (Stekel, 2003). One can group samples/genes using clustering methods or by
dimensionality reduction.
The goal of clustering methods is to form groups such that samples within a group
are more similar to one another than objects in different groups. From the clustering
algorithms, the hierarchical clustering is the most widely used for gene expression data
(reviewed in D’haeseleer, 2005; Kerr et al., 2008). This method produce a nested sequence
of clusters which can be graphically represented with a tree, called a dendogram. The
height of each horizontal line represents the distance between the two samples or clusters
that it merges, with greater heights representing greater distances. The hierarchical clus-
tering method begins with a distance matrix of the samples obtained with a similarity
measure (for example, Pearson correlation or Euclidean distance). After this, the nearest
samples are joined together in the tree to form a cluster. Then, a new distance matrix is
obtained substituting the clustered samples by the newly formed cluster. Once more, the
nearest samples or cluster of samples are clustered together and this is repeated until all
samples and clusters are linked (reviewed in D’haeseleer, 2005; Kerr et al., 2008).
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Principal Component Analysis (PCA)(Jollife, 1986) is a method that reduces the di-
mensionality of a high-dimensional data set, like microarrays with thousands of genes,
while retaining as much information as possible. Basically, PCA is a multivariate proce-
dure which rotates the existing axes to new positions in the space defined by the data,
such that maximum variabilities are projected onto the axes. Essentially, the set of cor-
related variables are transformed into a set of uncorrelated variables, called the principal
components. The principal components are linear combinations of the original variables,
and they are ordered by reduced variability. Singular value decomposition (SVD) is an
algorithm for computing the PCA of a non-symmetric matrix. This method is used in
microarray data analysis, since the data sets have different numbers of columns (samples)
and rows (genes). Methods based on principal components are not specifically intended
to discover groups, like the clustering methods, but to find structure in the expression
profiles. These methods have been successfully applied to microarray data (Palmer et al.,
2008; Hua et al., 2009).
1.3 Bioinformatic tools for large scale approaches
During the past few years, there have been enormous advances in genomics and molecular
biology. The challenge of interpreting the vast amounts of data from microarrays and
other high throughput technologies has led to the development of new tools in the fields
of computational biology and bioinformatics.
1.3.1 R and BioConductor
R is an open source system for statistical computation and graphics (Figure 1.9) (http:
//www.r-project.org/). It consists of a language plus a run-time environment with
graphics, a debugger, access to certain system functions, and the ability to run programs
stored in script files. This language is similar to the S language and environment which
was developed at Bell Laboratories (formerly AT&T, now Lucent Technologies) by John
Chambers and colleagues. There are some important differences, but much code written
for S runs unaltered under R.
R provides a wide variety of statistical (linear and nonlinear modelling, classical sta-
tistical tests, time-series analysis, classification, clustering, etc) and graphical techniques.
Moreover, R is highly extensible via packages. There are approximately 1900 packages
available through the Comprehensive R Archive Network (CRAN) of Internet sites cov-
ering a very wide range of modern statistics and interface to other computational sys-
tems/languages. For instance, RMySQL is a R package interface to the MySQL databases,
allowing the user to run multiple and complex queries using a local database.
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Figure 1.9: R system for statistical computation and graphics. Image obtained from (C)
R Foundation, http://www.r-project.org.
Bioconductor is an open source and open development software project to provide tools
for the analysis and comprehension of genomic data (http://www.bioconductor.org)
Bioconductor is based primarily on the R programming language, but does contain contri-
butions in other programming languages. Most Bioconductor components are distributed
as R packages, which are add-on modules for R. Initially most of the Bioconductor soft-
ware packages focused primarily on DNA microarray data analysis. As the project has
matured, the functional scope of the software packages broadened to include the analysis
of all types of genomic data, such as sequence or SNP data.
1.3.2 Molecular biology databases
Over the past few decades, major advances in the field of molecular biology, coupled with
advances in genomic technologies, have led to an explosive growth in the biological infor-
mation generated by the scientific community. This huge increase in genomic information
has led to an absolute requirement for computerized databases.
A database is a large and structured collection of data, usually associated with com-
puterized software designed to update, query, and retrieve components of the data stored
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within the system. A simple database might be a single file containing many records, each
of which includes the same type of information. Nowadays, one can find databases with
information relative to genomes, nucleotide sequences, genes, SNPs, proteins, microarray
data, etc. Moreover, this information is available not only for human but also for other
eukaryotic species and bacteria.
Most well known Genomic and Nucleotide databases are Entrez and Nucleotide databa-
ses (developed by National Center for Biotechnology Information - NCBI, http://www.
ncbi.nlm.nih.gov/), Ensembl (joint project between EMBL - EBI and the Wellcome
Trust Sanger Institute http://www.ensembl.org/index.html) and UCSC Genome Browser
(developed by University of California Santa Cruz, http://genome.ucsc.edu/). A major
advantage of these well structured and updated databases is the possibility to download
the entire database and run locally for multiple and complex searches.
Microarray and gene expression databases have been also growing and the more com-
monly used are Gene Expression Omnibus (GEO developed by NCBI, http://www.ncbi.
nlm.nih.gov/projects/geo/) and Array Express (developed by EBI-EMBL, http://
www.ebi.ac.uk/microarray-as/ae/). The submission to databases require microarray
data to comply with MIAME guidelines (Minimum Information About a Microarray Ex-
periment), which describes the minimum information that is needed to enable the inter-
pretation of the results of the experiment unambiguously and potentially to reproduce the
experiment (Brazma et al., 2001). The six most critical elements contributing towards
MIAME are:
1. The raw data for each hybridisation (e.g., CEL or GPR files);
2. The final processed (normalised) data for the set of hybridisations in the experiment
(study) (e.g., the gene expression data matrix used to draw the conclusions from the
study);
3. The essential sample annotation including experimental factors and their values (e.g.,
compound and dose in a dose response experiment);
4. The experimental design including sample data relationships (e.g., which raw data
file relates to which sample, which hybridisations are technical, which are biological
replicates);
5. Sufficient annotation of the array (e.g., gene identifiers, genomic coordinates, probe
oligonucleotide sequences or reference commercial array catalog number);
6. The essential laboratory and data processing protocols (e.g., what normalisation
method has been used to obtain the final processed data).
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The current count for available datasets on these databases is 13980 microarray exper-
iments for GEO (corresponding to 359915 samples hybridized) and 9164 for ArrayExpress
(260515 samples), from which 5620 are common to both databases.
1.4 Objectives
Differential alternative splicing has been associated with developmental stages, tissue types
and cancer (Matlin et al., 2005; Shin and Manley, 2004; Singh and Valca´rcel, 2005; Wang
and Cooper, 2007; Cooper et al., 2009). According to the current model, regulation
of alternative splicing uses combinatorial interactions of many positively and negatively
acting proteins, and specific splicing decisions most likely result from differences in the
concentration and/or activity of these proteins (Matlin et al., 2005; Shin and Manley,
2004; Singh and Valca´rcel, 2005). One should expect differential gene expression of splicing
factors through several cell types. The development of microarray technology allowed the
use of large-scale studies to systematically address this question.
The main goal of the present study has been to generate microarray-based predic-
tions for understanding the alternative splicing code that controls and coordinates the
transcriptome.
First, I have aimed to systematically assess by microarray data analysis the widespread
gene expression of splicing regulators during cell differentiation, in differentiated tissues
and in cancer. The identification of genes with differential expression can indicate putative
regulators for specific splicing decisions.
Finally, I have tried to establish the link between changes in splicing factors expres-
sion and alternative splicing profiles in cancer, combining results from gene and splicing
microarrays. The analysis centered in the identification of motifs enriched in the cancer-
associated splicing events that resemble binding sites for cancer misregulated splicing
factors.
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Chapter 2
Tissue-specific splicing factor gene
expression signatures
The original work described in this chapter has been published in: Grosso AR, Gomes AQ,
Barbosa-Morais NL, Caldeira S, Thorne NP, Grech G, von Lindern M, Carmo-Fonseca M
(2008) Tissue-specific splicing factor gene expression signatures, Nucleic Acids Research.
36(15):4823-32.
I would like to stress that some of the results presented and discussed in this section
are the product of collaborative work. Nuno Barbosa-Morais was responsible for selection
of splicing-related genes and annotation of microarray probes. Marieke von Lindern and
Godfrey Grech provided one of the microarray data sets for erythroid differentiation in
vitro. Anita Q. Gomes and Sandra Caldeira were responsible for the cell culture for val-
idation. Real-time quantitative PCR results were equally obtained by me and Anita Q.
Gomes.
Keywords: alternative splicing; splicing regulation; splicing factor; spliceosome
Abstract: The alternative splicing code that controls and coordinates the transcrip-
tome in complex multicellular organisms remains poorly understood. It has long been
argued that regulation of alternative splicing relies on combinatorial interactions between
multiple proteins, and that tissue-specific splicing decisions most likely result from differ-
ences in the concentration and/or activity of these proteins. However, large-scale data to
systematically address this issue have just recently started to become available. Here we
show that splicing factor gene expression signatures can be identified that reflect cell type
and tissue specific patterns of alternative splicing. We used a computational approach to
analyze microarray-based gene expression profiles of splicing factors from mouse, chim-
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panzee and human tissues. Our results show that brain and testis, the two tissues with
highest levels of alternative splicing events, have the largest number of splicing factor genes
that are most highly differentially expressed. We further identified SR protein kinases
and snRNP proteins among the splicing factor genes that are most highly differentially
expressed in a particular tissue. These results indicate the power of generating signature-
based predictions as an initial computational approach into a global view of tissue-specific
alternative splicing regulation.
2.1 Introduction
Alternative splicing generates multiple mRNA products from a single gene, thereby in-
creasing transcriptome and proteome complexity. In contrast to the prokaryotic rule of
one gene-one polypeptide, alternative splicing expands the protein coding potential of eu-
karyotic genomes by allowing a single gene to produce proteins with different properties
and distinct functions. Several studies based on large-scale expressed sequence tag (EST)
analysis estimated that >60% of human genes undergo alternative splicing, and this num-
ber more recently increased to >80% when microarray data became available (Black, 2003;
Matlin et al., 2005). Alternative splicing is regulated in response to signaling pathways,
and is specific to a developmental stage and tissue type.
The removal of introns from precursor mRNAs requires accurate recognition of splice
sites by the spliceosome, an assembly of uridine-rich small nuclear RNAs (U snRNAs)
packaged as ribonucleoprotein particles (snRNPs) that function in conjunction with nu-
merous non-snRNP proteins (Jurica and Moore, 2003; Nilsen, 2003). The selection between
different splice sites on a particular pre-mRNA substrate relies on an intricate interplay
involving the cooperative binding of trans-acting splicing proteins to cis-acting sequence
elements in the pre-mRNA. In mammals, these cis-elements include short and highly de-
generate 5′ and 3′ splice signals, additional regulatory sequences termed splicing enhancers
and silencers located in either exons or introns, the sizes of the exons and introns and sec-
ondary structures of the pre-mRNA. The trans-acting factors are commonly classified as
splicing activators or repressors depending on whether they facilitate or suppress the as-
sembly of snRNPs onto splice sites. However, many of these factors are also essential for
constitutive splicing, making it unrealistic to distinguish between proteins required for
the operation and regulation of the splicing reaction (Maniatis and Tasic, 2002; Shin and
Manley, 2004). Contrasting with the multitude of sequence-specific DNA-binding proteins
that control transcription, there are very few known regulatory proteins that selectively
control the splicing of specific genes. Although such factors exist, and a good example is
the brain-specific NOVA1 protein in mammals (Jensen et al., 2000), in the vast majority
28
2.2 Material and Methods
of cases splicing factors are ubiquitously expressed and modulate splicing of several genes
in distinct cell types. Indeed, specificity of splicing regulation is largely achieved with
nonspecific RNA-binding proteins (Singh and Valca´rcel, 2005).
According to the current view, regulation of alternative splicing uses combinatorial
interactions of many positively and negatively acting proteins. Tissue-specific splicing de-
cisions could therefore result from differences in the concentration and/or activity of these
proteins (Matlin et al., 2005; Shin and Manley, 2004; Singh and Valca´rcel, 2005). An
immediate prediction from this model is that the relative abundance of multiple splicing
proteins should differ in a tissue-specific manner. To explore this idea, we performed a
large-scale computational analysis of mRNA expression data obtained from DNA microar-
ray studies of different cell types and tissues derived from human, chimpanzee and mouse.
Our results show for the first time that splicing factor gene expression signatures can be
identified that correlate with tissue-specific patterns of alternative splicing.
2.2 Material and Methods
2.2.1 Selection of splicing-related genes
A list of 254 human splicing-related genes and several murine orthologues was previously
described (Barbosa-Morais et al., 2006). The remaining mouse genes were identified in
Ensembl (Hubbard et al., 2007) (http://www.ensembl.org), through the Family classi-
fication and BLAST (Altschul et al., 1990) search, and by searching SwissProt (Bairoch
et al., 2005) (http://us.expasy.org/sprot/) with appropriate keywords. Perl scripts,
relying on Bioperl (Stajich et al., 2002) (http://www.bioperl.org) and modules from
the Ensembl PERL API (Stabenau et al., 2004) were used for consistent annotation of
genes and subsequent cross-linking with the Affymetrix probe set annotation. Annotation
for the selected probe sets was validated with a Perl script. The first step of the pipeline
consisted in BLASTing (Altschul et al., 1990) and/or BLATing (Kent, 2002) each probe
against both the respective transcriptome (comprising RefSeq (Pruitt et al., 2007), Gen-
Bank (Benson et al., 2007) and transcripts from the UCSC Genome Browser database
(Kuhn et al., 2007)) and genome (Mouse mm8 and Human hg18, NCBI 36)). The pro-
gram subsequently parsed the outcome and extracted the associated transcriptomic and
genomic annotations from the tables in the UCSC genome annotation database (Kuhn
et al., 2007).
2.2.2 Microarray data pre-processing
All the microarray data analysis was done using R and several packages available from
CRAN (R Development Core Team, 2009) and Bioconductor (Gentleman et al., 2004).
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The raw data (CEL files) were normalized and summarized with the Robust MultiArray
Average method from the affy package (Gautier et al., 2004). An initial quality assessment
was done to remove microarrays with poor quality, using quality diagnostics with probe
level models and array quality control metrics for all arrays (average background was <
200, scale factors < 6, percentage of present calls, RNA degradation for GAPDH and
beta-actin - 3′/5′ ratio).
2.2.3 Cell culture and real-time quantitative PCR
C2 mouse myoblasts were cultured at 30% confluence in DMEM supplemented with 20%
FCS. For the differentiation experiments the cells were grown in DMEM containing 20%
FCS until they reached 90% confluency. At this stage the cells were changed to low serum
media (DMEM supplemented with 2% horse serum differentiation media) and allowed
to differentiate for a maximum period of four days. Primary mouse erythroid progenitors
were obtained from fetal livers of E12.5 mouse embryos and were subject to differentiation
in stem-Pro-34 medium supplemented with Epo and iron-saturated human transferrin as
described previously (Drissen et al., 2005). The C2 cell RNA samples used in the qRT-
PCR experiments were collected at days 0, 1 and 2 after changing to differentiation media.
Primary mouse erythroid RNA was collected at 0h, 24h, 36h, 48h and 60h after induction
of differentiation. The RNA was extracted using the RNeasy extraction kit according
to the manufacturer’s instructions (Qiagen) and treated with RNase-free DNaseI (Roche
Diagnostics) to remove any possible genomic DNA contaminant. The concentration of
RNA was determined using the Nanodrop (Nucliber) and RNA quality was assessed by gel
electrophoresis. Only samples yielding distinct 28S and 18S bands and A260/A280 ratios
between 1.8 and 2.1 were used in this study. Production of cDNA was carried out using
Superscript II reverse transcriptase following the manufacturers protocol (Invitrogen). 0.6
µg of total RNA were used in a 20 µl reaction volume. Isolated cDNA from brain, heart,
kidney, liver and testes was purchased from Ambion. A total of 30 ng of cDNA was used
for each SYBR Green measurement.
The primers used in the qRT-PCR assay (Annex Table A.1.1) were designed with
the Primer3 programme (Rozen and Skaletsky, 2000). The cDNA was amplified in 25 µl
reactions containing 50% of SYBR Green PCR master mix (Applied Biosystems). Primers
were added at a final concentration of 300nM, which proved to be the best concentration
for all the sets of primers tested. All reactions were performed in the ABI7000 Sequence
Detector (Applied Biosystems).
The relative quantification of mRNA levels at the various C2 differentiation stages was
calculated using 18S as an endogenous reference and the sample at day 0 as the calibrator.
For the erythropoiesis experiments we used Rnase Inhibitor as an endogenous reference
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and the sample at 0h as the calibrator. For the adult tissues experiments, RNU6A was
used as the endogenous reference. The quantities obtained for each gene were extracted
from a standard curve of CT versus quantity of mRNA obtained from a serial dilution
of either a mix of C2 cell cDNA extracts or a mix of erythropoietic progenitors at the
stages of differentiation used for the analysis. For tissue samples, the standard curve was
obtained from serial dilutions of a mix of all tissues.
2.3 Results
2.3.1 Splicing factor expression during cell differentiation
To study splicing factor expression during differentiation, we first established a list of
human and mouse genes associated with splicing and next we compared the corresponding
expression profiles from data sets obtained from microarray studies that analyzed cell
differentiation. A list containing 254 human genes associated with splicing was previously
reported by Barbosa-Morais et al. (2006).
Here, we searched for the respective orthologues in the mouse genome. Both human and
mouse lists contain genes that encode known splicing factors, spliceosome-associated pro-
teins, and proteins with a domain structure similar to bona fide splicing factors (Barbosa-
Morais et al., 2006). We selected transcript profiling studies performed with myotube,
adipocyte and erythroid cells differentiated in vitro and whole mouse testis collected from
birth to adulthood. In total we studied four distinct differentiation processes and for each
process we analyzed two independent data sets covering a total of 126 arrays (Table 2.1).
(Annex Table A.1.2). We identified 181 splicing-related genes (SRGs) for which 240 probe
sets are present in the Affymetrix Murine Genome U74v2 platform that was used in all
selected microarray studies (Annex Table A.1.3).
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All expression values were obtained from Gene Expression Omnibus (Barrett et al.,
2005) (http://www.ncbi.nlm.nih.gov/projects/geo). Data for myogenesis were ob-
tained from published studies using the in vitro model of C2C12 myoblasts undergoing
differentiation induced by serum restriction (Tomczak et al., 2004; Zhao et al., 2006).
Adipocyte differentiation in vitro was induced by hormonal treatment on two distinct
models: the 3T3-L1 preadipocyte cell line (Burton et al., 2004), and NIH-3T3 fibroblasts
(Akerblad et al., 2005). Two distinct cell models were also used to analyze erythroid differ-
entiation in vitro. One model consisted of G1E cells derived from GATA-1-null embryonic
stem cells; these cells proliferate in culture as immature erythroblasts and undergo ter-
minal erythroid maturation when GATA-1 function is restored (Welch et al., 2004). The
other model consisted of primary erythroid progenitors from mouse fetal livers; these cells
proliferate in serum-free medium under the control of erythropoietin (Epo), stem cell factor
(SCF) and dexamethasone (Dex), and undergo terminal differentiation when exposed to
Epo in the absence of SCF and Dex (Drissen et al., 2005). Spermatogenesis was examined
in vivo (Schultz et al., 2003; Shima et al., 2004).
To test whether the two data sets corresponding to the same differentiation process
were temporally synchronized, we performed a time-course analysis of the expression level
of the following differentiation marker genes: the muscle specific troponin C (Tnnc1)
(Hastings and Emerson, 1982) and Ca2+ channel ryanodine receptor 1 (Ryr1) (MacLennan
et al., 1990); the adipogenic complement factor D adipsin (Cfd) (Djian et al., 1985) and
peroxisome proliferator-activated receptor (Pparγ)(Akerblad et al., 2005); the erythroid
specific markers glycophorin A (Gypa) (Lahlil et al., 2004) and Slc4a1 (Paw et al., 2003);
the male germ cell lineage markers lactate dehydrogenase C (Ldhc) (Bonny et al., 1998) and
phosphoglycerate kinase 2 (Pgk2) (McCarrey et al., 1996). For myogenesis, adipogenesis,
and spermatogenesis the distinct data sets were approximately synchronous and were
directly used as biological replicates (Figure 2.1). For erythroid differentiation, maturation
of the cell type used in one study (G1E-ER4 cells) occurred significantly faster than that
of primary fetal liver progenitors used in the other study. This difference was corrected
considering that the last time points of both experiments were biologically equivalent
(Figure 2.1).
Next, for each differentiation process, we searched for variation in expression of splicing-
related genes along time. For each splicing-related gene on each data set, we estimated
the Pearson correlation coefficient between expression level and differentiation time point.
Only genes with absolute correlation values higher than 0.75 (p-values < 0.05, corrected
for multiple hypotheses testing using the Benjamini and Hochberg method (Benjamini
and Hochberg, 1995)) in both data sets were selected for further analysis. The Pearson
correlation coefficients of this subset of genes were used to cluster the microarray data
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(a) (b)
(c) (d)
(e)
Figure 2.1: Time-course analysis of the expression level of specific differentiation
marker genes. a) Myogenesis b) Adipogenesis c) Spermatogenesis d) Erythropoiesis non-
synchronized and e) Erythropoiesis after synchronization. The gene expression changes though
time for each data set are represented using the log2 intensities of the replicates (triangles and
circles) and the fitted loess smooth curves (dotted and solid lines).
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sets (Figure 2.2). The hierarchical clustering results revealed consistency between the
two data sets for each differentiation process, indicating that similar groups of genes
were found up- or down-regulated in the two independent experimental studies performed
with each cell type. The only exception was found for adipogenesis data sets, where the
different expression patterns for some splicing-related genes can be due to the distinct
cell lines used in both experiments. As shown in Figure 1, during myotube and erythroid
differentiation most splicing-related genes presented a negative correlation, meaning that
the expression decreased along time. In contrast, several splicing-related genes increased
expression during adipocyte and sperm cell differentiation.
2.3.2 Identification of cell-type specific variations in splicing factor ex-
pression
To identify cell-type specific variations in splicing factor expression, we had to compare
microarray data sets derived from different biological systems and experimental assays.
To address this issue, we developed a new approach that is based on regression modeling
methods. Polynomial models were fitted to the splicing factor expression profiles along
each differentiation process, and the best model was selected by the Akaike’s Information
Criterion in a Stepwise Algorithm (Hastie, 1992), as implemented in the stats package
(R Development Core Team, 2009). Since the selected regression models were essentially
linear or quadratic (meaning that gene expression variations were constant throughout
differentiation or showed only one inflexion point), for further analysis we reduced each
differentiation process to three time points, T0, T1 and T2 (Table 2.1). T0 corresponds
to the time when cultured cells were switched to differentiation medium or to the first day
postpartum for testis. T2 corresponds to terminally differentiated cells or adult testis, and
T1 corresponds to an intermediate stage specific to each differentiation process. During
myogenesis, the proliferating mononucleate myoblasts withdraw from the cell cycle and
subsequently fuse to form multinucleate myotubes; we therefore considered that T1 cor-
responds to the time when irreversible cell cycle withdrawal occurs, approximately 24h
after serum restriction (Tomczak et al., 2004). Likewise, for adipogenesis T1 corresponds
to the time when cells withdraw permanently from the cell cycle at approximately 2 days
after hormonal stimulation (Akerblad et al., 2005; Burton et al., 2004). In contrast, during
erythropoiesis cells undergo three to four rapid cell divisions accompanied by a decrease
in cell size and the accumulation of hemoglobin; in this case, we considered that T1 cor-
responds to the stage of proliferating capacity, which occurs at approximately 15h in GE1
cells and at 30h in fetal liver erythroid progenitors (Welch et al., 2004). Based on the
observation that >99% of male germ cell-specific transcripts are first expressed during or
after the occurrence of meiosis (Schultz et al., 2003), we considered the onset of sperm cell
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Figure 2.2: Variation in expression of splicing-related genes during cell differentiation.
Hierarchical clustering display of Pearson correlation values between gene expression and time, for
the splicing-related genes with the absolute correlation values higher than 0.75 in both data sets
of at least one differentiation process. The negative and positive correlation values are represented
by blue and red colours respectively.
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meiosis (taking place at approximately 14 days after birth) as T1 for spermatogenesis.
For each differentiation process, the fitted models were used to predict the splicing
factor expression levels at time points T0, T1 and T2. Then, to normalize the data, we
estimated the fold-changes observed at T1 and T2, relative to T0. We also transformed
the residual standard errors from each fitted regression model and used as weights (weights
= exponential (- residual standard error)) to include confidence levels of each prediction
(biological variability). Finally, the differentially expressed splicing-related genes for each
T1 and T2 differentiation stage were selected using linear models and empirical Bayes
methods (Smyth, 2004) as implemented in limma package (Smyth, 2005). The B-statistics
gives the log odds of differential expression and it requires an a prior value for the estimated
proportion of differentially expressed genes. To determine this value, we visually inspected
the volcano plot, which compares biological significance (represented by fold-changes) with
statistical significance (B-values) (Jin et al., 2001), finding the value which enabled genes
to be distinguished from the majority (Conboy et al., 2007). Additionally, we verified
the p-values corresponding to moderated F-statistics. Using the Benjamini and Hochberg
method (Benjamini and Hochberg, 1995), all genes selected as differentially expressed
had adjusted p-values lower than 0.01. To validate our approach we included in the
analysis the specific differentiation marker genes used for synchronization. Up-regulation
of each differentiation marker gene was specifically detected in the respective differentiation
process (see Figure 2.3).
Our analysis revealed that major variations in splicing factor expression occurred at T2.
The highest variation was found in spermatogenesis: 47% of total splicing-related genes
were up- or down-regulated at T2 relative to T0. The genes that were statistically selected
as up- or down-regulated in the different processes included members of the hnRNP and
SR protein families, SR protein kinases, DEAD-box RNA helicases, snRNP proteins and
several additional spliceosomal proteins (Annex Table A.1.4).
In order to validate the microarray data analysis we determined mRNA expression
levels using a more sensitive method. RNA samples were obtained from C2 myoblasts
and fetal liver erythroid progenitors and analyzed by quantitative real time PCR (qRT-
PCR). We started by selecting 12 genes that the microarray data analysis identified as up
or down-regulated during erythroid and myotube differentiation. As shown in Figure 2.4
(closed circles), expression changes were confirmed for 9 genes (75%). Thus, we obtained a
validation rate of 75% among independent biological samples for genes identified as differ-
entially expressed in our statistical analysis of microarray fold-changes. We then selected
15 other genes that were not identified as differentially expressed during myogenesis or
erythropoiesis. From these, we found 4 genes down-regulated in myogenesis (Rod1, Hn-
rpa1, Sfrs10, Hnrpa2b1) and 10 genes down-regulated in erythropoiesis (Cugbp1, Cugbp2,
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Figure 2.3: Splicing-related gene expression signatures during cell differentiation.
Heatmap with the fold-changes (log2) observed for each gene that is most highly differentially
expressed during myotube (Myo), adipocyte (Adip), sperm cell (Sperm) and erythrocyte (Ery)
differentiation. The genes and respective fold-changes are presented in detail in Annex Table
A.1.5. The side colours represent the splicing-related genes (yellow) and the specific differenti-
ation marker genes for myogenesis (Ryr1, Tnnc1 in blue), adipogenesis (Pparg and Cfd in red),
spermatogenesis (Ldhc, Pgk2 in green) and erythropoiesis (Gypa and Slc4a1 in grey).
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Ddx17, Snrpb2, U2af1, Sfrs2, Ptbp1, Hnrpdl, Hnrpr and Wtap) (open circles in Figure
2.4). This reveals that the microarray analysis is missing several genes the expression of
which is less obviously altered.
We next asked whether robust differences could be found that distinguish one dif-
ferentiation process from the others. To identify genes that are most highly differentially
expressed in a particular differentiation process we used linear models and empirical Bayes
methods (Smyth, 2004) as described previously. Following the statistical analysis, a filter
was applied to eliminate genes that were similarly differentially expressed in more than one
differentiation process. A gene is considered to be part of a signature when its expression
changes at least 1.5 fold (log2 = 0.58) more than in any other process. As shown in Figure
2.3 and Annex Table A.1.5, we identified gene expression signatures associated with 3
of the 4 differentiation processes. The list of genes in each signature included members
of the several splicing-related protein families. The gene expression signature associated
with spermatogenesis contained the highest number of genes. The signature associated
with erythroid differentiation consisted of two genes (U2af1-rs1 and Prpf6), and the adi-
pogenesis signature comprised three genes (Hnrpab, Hnrpdl, Sfrs1). No signature was
associated with myotube differentiation, as the genes that were differentially expressed
during myogenesis were also found differentially expressed in at least one of the other
processes analyzed. This may be related to the finding that splicing factors in muscle
are predominantly regulated at the post-transcriptional level (Kuyumcu-Martinez et al.,
2007).
2.3.3 Tissue-specific differences in splicing factor expression
Having identified splicing factor signatures associated with cell differentiation, we next
explored variations in splicing factor expression across tissues from human, chimpanzee
and mouse. Available mRNA expression data was obtained from a microarray study
covering five different tissues in six humans and five chimpanzees using a total of 48 hy-
bridizations (Khaitovich et al., 2005). This study used the Affymetrix Human Genome
hgu133plus2 platform containing 738 probe sets for 208 human splicing-related genes (An-
nex Table A.1.3). Gene expression profiles from adult mouse were obtained from a study
that analyzed 24 brain regions and 10 body tissues using a total of 150 array hybridiza-
tion measurements with the Affymetrix Murine mgu74av2 platform (Zapala et al., 2005)
(Annex Table A.1.6).
To compare the splicing-related gene expression profiles from human, chimpanzee and
mouse datasets, a linear model (Smyth, 2004) was fitted for each gene using the expression
values from all microarrays and with one regression coefficient for each tissue. Thus,
each regression coefficient from the model represents the expression level of the gene in a
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Figure 2.4: Validation of microarray data analysis for myogenesis and erythropoiesis
by quantitative real-time PCR. The fold-changes in expression of 27 splicing factors at T1
and T2 relative to T0 are indicated. For qRT-PCR analysis, RNA samples were obtained from
C2 myoblasts and fetal liver erythroid progenitors. Results are presented as means for at least
three independent experiments. Results from microarray data sets are presented as the fold-
changes estimated from the linear models. The dashed lines indicate the 1.5 fold-changes values
(in logarithm scale) for microarray data and qRT-PCR. The differentially expressed genes selected
by microarray data analysis for each differentiation stage are indicated with solid circles.
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Figure 2.5: Tissue expression profiles of splicing-related genes are similar in hu-
man, chimpanzee and mouse. Heatmap of adult mouse, chimpanzee and human tissues using
microarray-derived expression profiles of splicing-related genes. The expression value for each gene
is normalized across the samples to zero mean and one standard deviation for visualization pur-
poses. Genes with expression levels greater than the mean are colored in red and those below
the mean are colored in blue. The expression values for genes that are not present in one of the
microarray platforms are represented by white.
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different tissue. The tissues relatedness was studied performing a hierarchical clustering
analysis of the tissues expression profiles using only the splicing related genes and the non-
splicing related genes. We estimated the Euclidean distance among the tissues and used
hierarchical clustering with different agglomeration methods (complete, single, average,
centroid and Ward) as implemented in stats package (R Development Core Team, 2009).
The best hierarchical tree was chosen using the cophenetic correlation value. The results
revealed very similar expression profiles of splicing-related genes in human and chimpanzee
tissues (Figure 2.5).
For these two organisms, the testis was clearly an outlier, with low concordance in
expression of splicing-related genes relative to the other tissues examined. Analysis of
mouse tissues also indicated the testis as the main out-group (Figure 2.5). Most of the 24
mouse brain regions revealed high similarity in expression profiles and were mostly grouped
together for both splicing-related genes and all remaining genes (Figure 2.6). Pituitary
and retina appeared as an out-group of the brain cluster, and corpus plexus of the fourth
ventricle (Cp4v) did not group with the remaining brain regions but rather clustered with
the body tissues. Hierarchical clustering of splicing-related gene expression profiles in the
10 body tissues revealed the testis, spleen and thymus as the main out-group (Figure 2.6).
From the human, chimpanzee and mouse microarray data, we identified 154 genes that
were differentially expressed between brain, testis, heart, liver and kidney (Annex Table
A.1.7). From these, 7 genes were selected and 5 of them (71%) were found differentially
expressed by qRT-PCR (Figure 2.7).
Similarly to the results observed during cell differentiation, the differentially expressed
genes code for hnRNP and SR proteins, SR protein kinases, DEAD-box RNA helicases,
snRNP proteins, and several other splicing-related proteins. From the selected 154 genes,
104 showed tissue-specific expression variation higher than 1.5-fold in at least one of the
three organisms (Figure 2.8 and Annex Table A.1.8). Analysis of all mouse data sets
further revealed 74 genes with highest expression variation in the 24 brain regions and 10
body tissues (Annex Table A.1.9).
As shown in Figure 2.8, testis and brain contain the highest number of splicing-related
genes that are more than 1.5-fold differentially expressed. From the human and chim-
panzee microarray data sets, we identified 43 genes included in the testis-specific signa-
ture and 20 in the brain signature. From the mouse studies our results reveal 49 genes
in the testis signature and 6 in the brain signature. Out of the 48 genes included in the
signature for spermatogenesis (Annex Table A.1.5), 27 appeared also in the adult mouse
testis signature (Annex Table A.1.8 and Figure 2.9).
Concerning the brain-specific splicing factor gene expression signature, the gene list
includes the previously reported brain splicing regulators PTB1, NOVA1, A2bp1/FOX1,
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Figure 2.6: Hierarchical clustering of 24 mouse brain regions and 10 body tissues using
microarray-derived expression profiles for splicing-related genes (SRGs) and remain-
ing genes. The brain and body tissues are highlighted with green and yellow squares, respectively.
The brain regions are identified as follows: amygdala (Amg), bed nucleus of the stria terminalis
(Bnst), CA1 region of the hippocampus, CA3 region of the hippocampus, cerebellum (Cb), choroid
plexus from the fourth ventricle (cp4v), cortex (Cx), dentate gyrus (DG), diencephalon and mid-
brain excluding hypothalamus (Hy) (DiE-MD), entorhinal cortex (EntCx), hippocampal formation
(HiF), Hy, inferior colliculus (IC), medulla oblongata (MO), motor cortex (MtrCx), olfactor y bulbs
(Olf), periaqueductal gray (Pag), perirhinal cortex (PrhCx), pituitary (Pit), pons, retina, spinal
cord (SpCrd), striatum, and superior colliculus (SC). The height represents the value of the cri-
terion associated with the clustering method for the particular agglomeration, i.e., the distance
between each tissue.
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Figure 2.7: Validation of microarray data analysis for human tissues by quantitative
real-time PCR. The fold-changes in expression of 7 splicing factors between five different tissues:
brain, heart, kidney, liver and testes. qRT-PCR fold-changes were obtained from the ratios between
each tissue and the average of remaining tissues. Results from microarray data sets are presented as
the fold-changes estimated from the linear models. The dashed lines indicate the 1.5 fold-changes
values (in logarithm scale) for microarray data and qRT-PCR. The differentially expressed genes
selected by microarray data analysis for each tissue are indicated with solid circles.
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2.3 Results
Figure 2.8: Tissue-specific splicing-related gene expression signatures. Heatmap indi-
cating the fold-changes (log2) observed for each gene that is most highly differentially expressed
in the five tissues examined. The left bar highlights genes that are present in both human and
mouse Affymetrix platforms (green) or only in one of the two platforms (yellow). The genes and
respective fold-changes are presented in detail in Annex Table A.1.8.
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and members of the CELF/BRUNOL and ELAVL families. Additionally, we identified the
non-SR splicing regulator Y-box protein 1 (Stickeler et al, 2001) highly down-regulated
and the core snRNP protein SmN (Grimaldi et al, 1993) highly up-regulated. We detected
many genes that were highly differentially expressed in chimpanzee but not in human brain,
and we found two genes (TNRC4, encoding the CELF3/BRUNOL1 protein, and LSM8,
encoding the U6 snRNA-associated Sm-like protein LSm8) that were, respectively, highly
up- and down-regulated in human but not in chimpanzee brain.
The testis-specific signature included the splicing factor 3a subunit 2 (SF3A2) and
the SR protein kinases 1 and 2 (SRPK1 and SRPK2). The genes that were common to
the testis-specific signatures from all three organisms (human, chimpanzee and mouse)
encode SF3A2, SRPK2, protein phosphatase 1G (PPM1G), the RNA binding protein
RDBP and the heterogeneous nuclear ribonucleoprotein HNRPLL. Remarkably, 10 (37%)
of the mouse genes included in the testis-signature corresponded to up-regulated snRNPs
(Lsm2, Lsm4, Sf3a3, Snrpa, Snrpa1, Snrpc, Snrpd2, Snrpg, Usp39 and U5-40d).
2.4 Discussion
In this study we applied computational methods to identify tissue-specific splicing factor
gene expression signatures from published microarray data sets. By using this approach we
have identified over 100 splicing related genes that are most highly differentially expressed
in a particular tissue or differentiation process.
Recently, several microarray-based methods have been reported for genome-wide mon-
itoring of splicing events in mammalian tissues (Blencowe, 2006; Wang and Cooper, 2007).
The increasing availability of splicing-microarray data sets will make it possible to extend
our approach and systematically search for differential expression of alternatively spliced
isoforms of splicing regulators. Importantly, however, changes in splicing factor mRNA lev-
els may not necessarily reflect on protein expression due to post-transcriptional regulation
(Boutz et al., 2007; Makeyev et al., 2007). Therefore, further experimental investigation
on the candidate tissue-specific splicing regulators identified in this study is required to
determine whether specific changes in the protein concentration and/or activity do occur.
2.4.1 Splicing factor signatures correlate with tissue-specific alternative
splicing patterns
By using a method that normalizes the number of observed alternative splicing events
to the EST coverage in each tissue, Yeo and colleagues found that the brain has the
highest proportion (>40%) of alternatively spliced genes, followed by the liver and testis
(Yeo et al., 2004). The brain and testis showed the highest levels of exon skipping, while
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2.4 Discussion
Figure 2.9: Comparison of expression fold-changes (log2) observed for 48 mouse splicing
factors during testis differentiation (T2 vs T0) and in adult tissue (testis vs remaining
tissues). The contradictory fold-changes observed for Rbms1 were obtained from two Affymetrix
probes sets that hybridize in different regions of the gene (alternative exon and 3′UTR).
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the liver had the highest frequency of alternative 3′ and 5′ splice site usage. Using a
microarray platform with probes that span exon-exon junctions, Pan et al (2004) detected
the largest number of tissue-dependent alternative splicing events associated with brain.
A more recent analysis performed with human exon microarrays revealed that testis and
brain express the largest number of probesets that are not expressed in any other tissue
(Clark et al., 2007). In that study, tissue-specific probesets may be from genes that are
only expressed in a single tissue, or individual exons that are included in a tissue-specific
manner via alternative splicing (Clark et al., 2007).
Our analysis revealed that the highest number of highly differentially expressed splicing-
related genes occurred in the testis and in the brain, whereas the liver showed higher
concordance in expression of splicing-related genes relative to other tissues, namely the
kidney. Thus, our results specifically distinguish the two tissues with highest abundance
of alternatively spliced mRNA isoforms that differ by inclusion or exclusion of an exon,
as those with a highest variation in splicing factor expression. Yeo and coauthors (2004)
have also analyzed microarray expression data for 20 splicing factors of the SR, SR-related
and hnRNP protein families across several human tissues and identified liver as an outlier,
suggesting an involvement of this group of factors in regulation of liver-specific alternative
3′ and 5′ splice decisions. However, our analysis revealed that variation in expression levels
of these factors is not unique to the liver.
2.4.2 SR protein kinases as tissue-specific signatures
According to a current model, small differences in concentration or activity of SR proteins
may influence the choice of competing splice sites and therefore control alternative splicing
(Shin and Manley, 2004). SR proteins form multiprotein complexes that bind to splicing
enhancer sequences in the pre-mRNA and stabilize the assembly of the spliceosome at
splice sites. One possible mechanism to affect SR protein activity is differential phospho-
rylation. Indeed, the phosphorylation status of Ser residues within the RS domain of SR
proteins has been shown to alter protein-protein interactions and splicing activity (Prasad
et al., 1999; Prasad and Manley, 2003; Xiao and Manley, 1997). Several SR-protein ki-
nases have been identified, including SRPK and CLK/STY (Colwill et al., 1996; Gui et al.,
1994). Here, we detected members of both the SRPK and CLK gene families being differ-
ently expressed in distinct cell types and tissues. In particular, the SRPK1 and SRPK2
genes were highly up-regulated during mouse spermatogenesis. Moreover, SRPK1 and
SRPK2 were included in the testis-specific signature for chimpanzee and mouse (SRPK2
also found for human), whereas SRPK3 was included in the heart signature for human and
chimpanzee. We therefore predict that SR protein kinases are likely to play an important
role in tissue-specific alternative splicing.
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2.4.3 Tissue-specific signatures include several snRNP proteins
It is generally assumed that splicing is regulated by non-snRNP proteins that modulate
the association of core components of the spliceosome with the pre-mRNA. This view was
for the first time questioned by an RNAi screen in Drosophila cells that unexpectedly de-
tected changes in alternative splicing of endogenous genes after reducing the levels of core
spliceosomal proteins (Park et al., 2004). These included components of the U1, U2 and
U4/U6 snRNPs, and both subunits of the U2 snRNP auxiliary factor, U2AF. More re-
cently, we used RNAi to down-regulate expression of the small subunit of U2AF in human
cells and we also observed changes in alternative splicing of transcripts derived from both
endogenous genes and exogenous reporter minigenes (Pacheco et al., 2006b, a). In another
study, Massiello and coauthors (2006) reported that RNAi-mediated down-regulation of
SAP155 (a subunit of splicing factor SF3B, which associates with the U2 snRNP) affected
alternative splicing of Bcl-x transcripts. Although some of the effects on alternative splic-
ing induced by RNAi may be indirect, it was also shown that in Saccharomyces cerevisiae
substrate selectivity can be modulated by altering the kinetics of spliceosome rearrange-
ment (Query and Konarska, 2004). Further support for the idea that fluctuations in the
concentration of core spliceosomal proteins may contribute to regulate splicing is provided
by the differential cell type and tissue-specific expression profiles presented in this study.
Variations in expression of genes that code for Lsm, Sm and snRNP-specific proteins were
detected in the course of myotube, erythroid and sperm cell differentiation. Consistent
with our results, down-regulation of snRNP synthesis during myogenesis was previously
demonstrated by pulse-labeling experiments (Gabanella et al., 2005). A decrease in expres-
sion of genes that encode snRNP proteins was not observed during adipogenesis, arguing
that the variations detected in myogenesis are not related to the cell cycle arrest, which
is common to both myotube and adipocyte differentiation. In addition to core snRNP
proteins, the U2af1-rs1 gene, which encodes a protein with a high degree of homology to
the small subunit of U2AF (Mollet et al., 2006), was found specifically up-regulated during
erythroid differentiation. Another U2AF-related gene, U2af1-rs2, was highly up-regulated
in the mouse brain. SF3A2 was further identified as part of the testis-signature for hu-
man, chimpanzee mouse, while the snRNP protein SmN appeared in the brain-signature
for the three organisms. Clearly, a major task for the future will be to determine whether
tissue-specific alternative splicing events are regulated by the differential expression of
these snRNP and snSNP-related proteins.
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Chapter 3
Cancer-specific misregulation of
splicing factor gene expression
Part of the introduction and discussion of this chapter is written as a review article in:
Grosso AR, Martins S, Carmo-Fonseca M. (2008) The emerging role of splicing factors in
cancer, EMBO Rep, 2008 Nov;9(11):1087-93. I would like to stress that Sandra Martins
and I contributed equally to this article.
The original work described in this chapter is in preparation for submission to a peer
reviewed journal.
Keywords: splicing of pre-mRNA; splicing factor; spliceosome; cancer
Abstract: Recent progress in global sequence and microarray data analysis has re-
vealed the increasing complexity of the human transcriptome. Alternative splicing gener-
ates a huge diversity of transcript variants and disruption of splicing regulatory networks
is emerging as a major contributor to various diseases, including cancer. Current efforts
to establish the dynamic repertoire of transcripts that are generated in health and disease
are showing that many cancer-associated alternative splicing events occur in the absence
of mutations in the affected genes. Rather, a growing body of evidence reveals changes
in splicing factor expression that correlate with cancer development, progression and re-
sponse to therapy. To explore this idea, we performed a large-scale analysis of expression
profiles for several splicing factors. Cancer-specic alterations in gene expression were found
for the major splicing protein families: snRNPs, hnRNPs, SRs, SR-kinases and splicing
regulators. The majority of differentially expressed splicing regulators were up-regulated
in cancer and some misregulations appear consistently in several cancer types.
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3.1 Introduction
Removal of noncoding sequences (introns) from precursor messenger RNAs (pre-mRNAs)
through splicing provides a versatile means of genetic regulation. Alternative splicing
allows a single gene to generate multiple transcripts, thus expanding the transcriptome and
proteome diversity in metazoans. Several studies based on large-scale expressed sequence
tag (EST) analysis estimated that >60% of human genes undergo alternative splicing,
and this number more recently increased to >80% when microarray data became available
(Black, 2003; Matlin et al., 2005).
Intron excision is carried out by an assembly of small nuclear ribonucleoprotein par-
ticles (snRNPs) and extrinsic, non-snRNP protein splicing factors that are collectively
recruited to pre-mRNAs and form the spliceosome. The initial events of spliceosome as-
sembly require the recognition of specific sequences located at and near the 5′ and 3′
splice sites, which recruit the U1 and U2 snRNPs. In metazoan organisms, the splice site
sequences are weakly conserved and require specific additional RNA sequence elements
that function to either enhance or repress the ability of the spliceosome to recognize and
select nearby splice sites (Maniatis and Tasic, 2002; Matlin et al., 2005). The multiplic-
ity of protein-protein and protein-RNA interactions that modulate the association of the
spliceosome with the pre-mRNA constitutes the basis to control alternative splicing.
A typical multiexon pre-mRNA can undergo a number of alternative splicing patterns
(Black, 2003). Most exons are constitutive, meaning that they are always included in the
final mRNA, but there are also regulated exons, which are sometimes included and some-
times excluded from the mRNA. Exons can also be lengthened or shortened by altering
the position of one of their splice sites, or by a distinct splicing pattern that consists in
failure to remove an intron, a process known as intron retention. Alternative splicing can
also be coupled to differential promoter or polyadenylation site usage, giving rise to an
even larger transcriptome heterogeneity.
Splicing abnormalities play an important role in human diseases such as cancer (Wang
and Cooper, 2007). Several mutations are known that affect the splicing of oncogenes,
tumour suppressors and other cancer-relevant genes (Srebrow and Kornblihtt, 2006; Ven-
ables, 2006), however, many splicing abnormalities identified in cancer cells are not asso-
ciated with mutations in the affected genes. Rather, a growing body of evidence indicates
that the splicing machinery is a major target for misregulation in cancer. According to
recent bioinformatics studies, changes in splicing factor expression may play a key role
in the general splicing disruption that occurs in many cancers (Kim et al., 2008; Ritchie
et al., 2008).
To systematically investigate the splicing factor expression variations in cancer, we
performed a large-scale analysis of expression profiles in cancer for several genes encoding
52
3.2 Material and Methods
Table 3.1: Microarray data sets used to study several cancer types. The microarray
datasets were grouped according to general cancer tissue and cancer type. GEO (“GSExxxxx”)
and ArrayExpress (“E-xxxxx”) accession numbers and reference to published work (if available)
are provided.
General Can-
cer Tissue
Cancer Type Database
Acession
Number
References
Bladder GSE3167 Dyrskjot et al. (2004)
Brain Glioblastoma E-MEXP-567 Margareto et al. (2007)
Astrocytoma E-MEXP-567 Margareto et al. (2007)
Breast Invasive breast carcinoma GSE3744 Richardson et al. (2006)
Colon GSE4107 Hong et al. (2007)
Esophagus Barrett’s-associated adenocar-
cinomas
GSE1420 Kimchi et al. (2005)
Head and neck Head and neck squamous cell
carcinoma
GSE6631 Kuriakose et al. (2004)
Kidney Renal cell carcinoma GSE6344 Gumz et al. (2007)
Liver Hepatocellular carcinomas E-TABM-36 Boyault et al. (2007)
Lung Squamous cell lung cancer GSE3268 Wachi et al. (2005)
Lung Adenocarcinoma E-MEXP-231 Yap et al. (2005)
Neuroblastoma E-MEXP-669 De Preter et al. (2006)
Prostate GSE3325 Varambally et al. (2005)
Thyroid Papillary thyroid cancer GSE3678 unpublished
Vulva Vulvar intraepithelial neopla-
sia
GSE5563 Santegoets et al. (2007)
proteins shown to be involved in the splicing process.
3.2 Material and Methods
3.2.1 Data selection
Microarray data sets for assessment of splicing factors expression were selected from previ-
ous studies for several cancer types (Table 3.1). We selected microarray data sets for which
the hybridizations were done using Affymetrix GeneChip 3′ Expression Arrays (platforms
hgu95a, hgu95av2, hgu133a, hgu133b and hgu133plus2) and the biological samples were
from biopsy samples (no cell lines) for the cancer and corresponding normal tissue. A list
containing genes that encode known splicing factors, spliceosome-associated proteins, and
proteins with a domain structure similar to bona fide splicing factors was obtained from
previous studies (Barbosa-Morais et al., 2006; Chen et al., 2007).
3.2.2 Microarray data analysis
All the microarray data analysis was done using R and several packages available from
CRAN (R Development Core Team, 2009) and Bioconductor (Gentleman et al., 2004).
The raw data (CEL files) for Affymetrix GeneChip 3′ Expression Arrays was normalized
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and summarized with the Robust MultiArray Average method from the affy package
(Gautier et al., 2004). An initial quality assessment was done to remove microarrays with
poor quality, using quality diagnostics with probe level models and array quality control
metrics for all arrays (average background was < 200, scale factors < 6, percentage of
present calls, RNA degradation for GAPDH and beta-actin - 3′/5′ ratio).
The differentially expressed splicing-related genes for each cancer type were selected
using linear models and empirical Bayes methods (Smyth, 2004) as implemented in limma
package (Smyth, 2005). The B-statistics gives the log odds of differential expression and
it requires an a priori value for the estimated proportion of differentially expressed genes.
To determine this value, we visually inspected the volcano plot, which compares biologi-
cal significance (represented by fold-changes) with statistical significance (B-values) (Jin
et al., 2001), finding the value which enabled genes to be distinguished from the majority
(Conboy et al., 2007). Additionally, we verified the p-values corresponding to moder-
ated F-statistics, adjusted using the Benjamini and Hochberg method (Benjamini and
Hochberg, 1995).
3.2.3 Functional analysis
The statistically overrepresented Gene Ontology (GO) terms within up-regulated genes
was assessed using GOstat (Beissbarth and Speed, 2004). The program determines which
GO terms are enriched in an input gene list relative to the reference genes (all the genes
present in the microarray platform) using Fisher’s Exact Test (Fisher, 1935).
3.3 Results
3.3.1 Up-regulation of splicing factors in cancer
To study cancer-associated changes in splicing factor expression and other splicing-related
genes we analysed 14 microarray expression data sets previously published and containing
cancer samples and corresponding normal tissue (Table 3.1). The cancer data sets were
classified according to general cancer tissue (bladder, brain, breast, colon, esophagus, head
and neck, kidney, lung, neuroblastoma, prostate, thyroid and vulva cancers) and also the
cancer type for cases previously shown to present different histological or gene expression
profiles, namely glioblastoma and astrocytoma for brain cancer (Margareto et al., 2007)
and squamous cell and adenocarcinoma for lung cancer (Wistuba and Gazdar, 2006).
A list of 262 splicing-related genes (SRGs) was obtained from previous studies and
contained genes that encode known splicing factors, spliceosome-associated proteins, and
proteins demonstrated by mass spectrometry or predicted by sequence homology to in-
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teract with the pre-mRNA or the spliceosome (Barbosa-Morais et al., 2006; Chen et al.,
2007) (Annex Table A.2.1).
In total 192 splicing-related genes were found to be misregulated in cancer (Figure
3.1 and Annex Table A.2.2). The genes with expression variations encoded for the major
splicing protein families snRNPs, hnRNPs, SRs, SR-kinases, RNA-helicases-like and other
splicing regulators.
Some cancers presented a higher number of misregulated splicing-related genes, namely
bladder, brain, kidney, lung and vulva cancers (Table 3.2). Although, these cancers pre-
sented also a higher number of differentially expressed genes, the percentage of SRGs
relative to all misregulated genes was higher than for the remaining cancers (2.14 - 5.01%
compared to 0.30 - 1.89%).
The results revealed that the majority of misregulated splicing regulators were up-
regulated in cancer (Table 3.2). Indeed, the proportion of up-regulation was higher for
SRGs than when considering all genes up-regulated on each cancer type.
One could suggest that the up-regulation of SRGs was due to an overall increase of the
gene expression pathway. We therefore assessed the enrichment of Gene Ontology (GO)
terms associated with gene expression (namely terms like transcription, RNA processing,
translation, protein maturation and offspring terms) for all up-regulated genes. Using all
the overexpressed genes (not only the splicing regulators) we select enriched GO terms
(p-value < 0.01, with Benjamini correction for multiple testing) associated with gene
expression and offspring terms. An overall concordance was observed between the number
of up-regulated splicing regulators and the enrichment of RNA-processing related terms
for each cancer type (Table 3.2). Bladder, brain, lung and vulva cancers that contained
the higher number of up-regulated splicing regulators also presented an enrichment of GO
terms for RNA-splicing. Some of these cancers also presented enriched GO terms related
to transcription and translation, however these were not found simultaneously in the same
cancer type and they were related to partial steps, namely transcription and translation
initiation. Thus, these results suggest that the up-regulation is mostly confined to the
RNA-processing machinery.
Although our results reflect variations at RNA level, previous studies have shown
cancer-specific increased levels of proteins encoded by transcripts that we identified as
up-regulated in cancers compared to the corresponding normal tissue: HNRNPA2B1 in
lung (Sueoka et al., 2001), PTB (PTBP1) in glioblastoma (Jin et al., 2003a), ASF/SF2
(SFRS1) in lung (Karni et al., 2007), SRPK1 in breast (Hayes et al., 2006).
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Figure 3.1: Splicing-related genes misregulated in cancer. The splicing factors are organized
according to the major families: small nuclear ribonucleoproteins that combine with pre-mRNA
and various proteins to form spliceosomes (snRNP); heterogeneous nuclear ribonucleoproteins (hn-
RNP); Serine/Arginine-rich proteins (SR); SR-kinases (Kinases); RNA-helicases and other splicing-
related proteins (Other SRGs). Fold-changes values for up and down-regulation values in cancer
are represented by red and blue colours according to legend (for more details see Annex Table
A.2.2).
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To evaluate the impact of the cancer-associated variations, we decided to assess the
expression of the misregulated splicing-related genes in the original normal tissue. Using a
microarray data set containing six of the normal human tissues here analysed (GSE1133,
Su et al. (2004)) and applying a computational approach previously described (Grosso
et al., 2008), we identified splicing-related genes that are most highly differentially ex-
pressed in a particular tissue (Figure 3.2). Comparing the results from both analyses we
could detect that some of some up or down-regulated splicing factors in a specific tissue
appear misregulated in the corresponding cancer. Namely, the up-regulated genes PTB
(PTBP1) and HNRPAB in brain cancer (astrocytoma and glioblastoma) showed previ-
ously lower expression in brain comparative to other normal tissues and are up-regulated
in brain cancer. In opposition, the A2BP1 (FOX1) presented higher expression in brain
and it is down-regulated in brain cancer.
Similarly, HNRPA3 and SRPK1 presented lower expression in normal lung when com-
pared to other normal tissues and they are up-regulated in lung adenocarcinoma. Thus,
these splicing-related genes with tissue-specific expression profiles affected are potential
candidates for alternative splicing misregulation in respective cancer tissues.
3.3.2 Cancers share common misregulated splicing factors
Our results showed splicing-related genes commonly misregulated in several cancer types
(Figure 3.3). Similar up-regulation was found in at least four cancer types for genes
encoding hnRNPs (HNRPA2B1, HNRNPAB, SYNCRIP - hnRNP Q), SR (SF2/ASF -
SFRS1, TRA2-β1 - SFRS10, SFRS2 - SC35), SR kinases (SRPK1), snRNP associated
proteins (PRPF40A, SNRPA1, SNRPB, SNRPD1, SNRPE, SNRPG, LSM5) and other
regulators (YBX1, ELAVL1, NONO). Common down-regulation to three cancer types
was observed for hnRNP E2 (PCBP2), CUGP2, FOX1 (A2BP1) and SNRPN.
Our results increased the number of cancer-associated misregulations for some splicing
factors previously associated to a single or few cancer types: SC35 (SFRS2) up-regulation
in ovary cancer (Fischer et al., 2004); TRA2-β1 (SFRS10) up-regulation in breast can-
cer (Watermann et al., 2006); HNRPA2B1 up-regulation in lung cancer (Sueoka et al.,
2001); PTB up-regulation in ovary (He et al., 2004) and glioblastoma (Jin et al., 2003a);
YBX1 up-regulation in ovary (Fischer et al., 2004); HuR (ELAVL1) up-regulation in
breast (Denkert et al., 2004) and ovary cancers (Izquierdo, 2008); Sam68 (KHDRBS1) up-
regulation in prostate cancer (Busa` et al., 2007); hnRNP E2 (PCBP2) down-regulation in
oral cancer (Roychoudhury et al., 2007); SF1 down-regulation in colon cancer (Shitashige
et al., 2007b, a) and RBM5 (LUCA15) down-regulation in lung cancer (Oh et al., 2006).
Recent studies also demonstrated that some cancers could present common misregu-
lated splicing factors. Over-expression of the splicing factor SF2/ASF (SFRS1) at protein
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Figure 3.2: Tissue-specific splicing factors misregulated in cancer. For each tissue are
represented the genes with expression variations (fold-changes) relative to the remaining normal
tissues (first column) and misregulated in corresponding cancer (second column). Fold-change val-
ues for up and down-regulation values in cancer are represented by red and blue colours according
to legend. The splicing factors are organized according to the major families: small nuclear ribonu-
cleoproteins that combine with pre-mRNA and various proteins to form spliceosomes (snRNP);
heterogeneous nuclear ribonucleoproteins (hnRNP); Serine/Arginine-rich proteins (SR); SR-kinases
(Kinases); RNA-helicases and other splicing-related proteins (Other factors).
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Figure 3.3: Common misregulated splicing factors in cancer. The splicing factors are
organized according to the major families: small nuclear ribonucleoproteins that combine with
pre-mRNA and various proteins to form spliceosomes (snRNP); heterogeneous nuclear ribonucle-
oproteins (hnRNP); Serine/Arginine-rich proteins (SR); SR-kinases (Kinases); RNA-helicases and
other splicing-related proteins (Other SRGs). Fold-change values for up and down-regulation val-
ues in cancer are represented by red and blue colours according to legend (for more details see
Annex Table A.2.2).
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level and splicing modulation of tumour suppressor genes was recently shown for vari-
ous human tumours: colon, thyroid, small intestine, kidney and lung (Karni et al., 2007).
SRPK1 protein overexpression was also detected in several cancer: pancreas, breast, colon,
T-cells and chronic myelogenous leukaemia (Hayes et al., 2006). Another study found
FOX2 (RBM9) down-regulated in ovarian cancer and misspliced in breast cancer, lead-
ing to an overall depletion of FOX2 protein and splicing modulation (Venables et al.,
2009). Interestingly, our results suggest that these variations can be extended to more
cancers for SF2/ASF (bladder, brain and vulva cancers), SRPK1 (bladder, lung cancers
and neuroblastoma) and FOX2 (prostate and vulva cancers).
3.4 Discussion
In this study we applied computational methods to identify splicing factor gene expression
variation associated with cancer. We have identified cancer misregulation for 192 splicing-
related genes encoding the major splicing protein families snRNPs, hnRNPs, SRs, SR-
kinases, RNA-helicases-like and other splicing regulators. The majority of differentially
expressed splicing regulators were up-regulated in cancer and some misregulations appear
consistently in several cancer types.
Previously, Kirschbaum-Slager et al. (2004) using serial analysis of gene expression
(SAGE) and Oncomine (microarray-based information) also observed over-expression of
splicing factors as general trend in breast, colon, prostate and brain cancers. Importantly,
however, changes in splicing factor mRNA levels may not necessarily reflect on protein
expression due to post-transcriptional regulation, namely through mediation by miRNA
regulation (Boutz et al., 2007; Makeyev et al., 2007). Several studies have shown that
expression of miRNAs is altered in cancer and that there is a strong correlation between
abrogated expression of miRNAs and oncogenesis (Esquela-Kerscher and Slack, 2006).
Therefore, experimental investigation of the candidate cancer splicing regulators identified
in this study is required to determine whether specific changes in the protein concentration
and/or activity do occur.
3.4.1 Can splicing factors act as oncogenes?
Because changes in the concentration, localization and/or activity of splicing factors are
known to modify the selection of splice sites (Matlin et al., 2005), it is predicted that
the abnormally expressed splicing factors found in tumour cells induce the production
of mRNA isoforms that were either non-existing or less abundant in normal cells. This
phenomenon might contribute directly or indirectly to cancer development, progression
and/or response to therapy. A recent study demonstrated for the first time that over-
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Table 3.3: Splicing factors altered in cancer and potential splicing target.
Name (other
names)
Cancer tissue Affected
mRNA
References
Up-regulated in cancer
SR and SR-related proteins SF2/ASF
(SFRS1)
Colon, thyroid, small
intestine, kidney, lung,
breast
RON, BIN1,
S6K1MNK2
Ghigna et al.
(2005); Karni et al.
(2007)
SC35 (SFRS2) ovary - Fischer et al.
(2004); Xiao et al.
(2007)
SRp20
(SFRS3)
ovary MRP1 He et al. (2004)
SRp40
(SFRS5)
breast CD44 Huang et al. (2007)
SRp55
(SFRS6)
breast - Karni et al. (2007)
Tra2-1
(SFRS10)
breast CD44 Watermann et al.
(2006)
SRm160
(SRRM1)
Thymic ephitelium,
stomach and kidney
CD44 Cheng and Sharp
(2006); Harn et al.
(1996); Lee et al.
(2003b); Wu et al.
(2003)
hnRNP proteins hnRNPA1
(HNRNPA1)
Lung, breast, ovary - Patry et al. (2003);
Zerbe et al. (2004)
hnRNPB1
(HN-
RNPA2B1)
Lung - Sueoka et al.
(2001); Zhou et al.
(1996)
hnRNPF
(HNRNPF)
colon - Balasubramani
et al. (2006)
hnRNPL (HN-
RNPL)
Esophageal cancer cell
lines
- Qi et al. (2008)
hnRNPK
(HNRNPK)
Colorectal, oral - Carpenter et al.
(2006); Roychoud-
hury and Chaud-
huri (2007)
PTB
(PTBP1)
Gliobastoma, ovary FGFR1, MRP1 Jin et al. (2003a);
He et al. (2004)
Other factors YB-1 (YBX1) Ovary CD44 Fischer et al.
(2004)
SPF45
(RBM17)
Bladder, breast, colon,
lung, ovary, pancreas
and prostate
FAS Corsini et al.
(2007); Sampath
et al. (2003)
SRPK1
(SRPK1)
Pancreas, breast,
colon, T-cells, Chronic
myelogenous leukemia
MAP2K2 Hayes et al. (2006)
HuR
(ELAVL1)
Breast, ovary FAS Denkert et al.
(2004); Izquierdo
(2008)
HuD
(ELAVL4)
Leukaemia T-ALL IK Bellavia et al.
(2007)
Sam68
(KHDRBS1)
prostate - Busa` et al. (2007)
Down-regulated in cancer
hnRNP proteins hnRNP E2
(PCBP2)
oral - Roychoudhury
et al. (2007)
Other factors U2AF35
(U2AF1)
Pancreas CCK-B Ding et al. (2002);
Pacheco et al.
(2006b)
SF1 (SF1) Colorectal WISP1,
FGFR3
Shitashige et al.
(2007a, b)
RBM5
(LUCA15)
lung - Oh et al. (2006)
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expression of a splicing factor can indeed trigger malignant transformation (Karni et al.,
2007). The authors showed that the splicing factor SF2/ASF is up-regulated in various
human tumours and affects alternative splicing of the tumour suppressor BIN1 and the
kinases MNK2 and S6K1. The resulting BIN1 isoforms lack tumor-suppressor activity, the
MNK2 isoform promotes MAP kinase-independent eIF4E phosphorylation, and the S6K1
isoform has demonstrated oncogenic properties (Karni et al., 2007). This study serves
as a proof-of-principle and shows that abnormally expressed splicing proteins can have
oncogenic properties.
A previous study had indicated that SF2/ASF affects alternative splicing of Ron, a ty-
rosine kinase receptor involved in cell dissociation, motility, and matrix invasion (Ghigna
et al., 2005). An alternatively spliced isoform of Ron that lacks exon 11 produces a consti-
tutively active protein that is expressed in gastric, breast and colon cancers and induces
an invasive phenotype (Collesi et al., 1996; Ghigna et al., 2005). Binding of SF2/ASF to
a regulatory sequence in exon 12 stimulates skipping of exon 11, and overexpression of
SF2/ASF activates cell locomotion. This effect can be reversed by specific knockdown of
the alternatively spliced Ron isoform, suggesting that an up-regulation of SF2/ASF could
contribute to malignant transformation by inducing alternative splicing of Ron.
Several additional splicing proteins have been detected to be up-regulated in various
human tumours (Table 3.3), but in most cases the effect that these changes have on
splicing regulation is unknown. In contrast, the number of splicing proteins that have
been detected to be down-regulated in cancer is much lower (Table 3.3). For example,
reduced expression of U2AF35 was found in pancreatic cancer cells and correlated with
missplicing of the cholecystokinin-B/gastrin (CCK-B) receptor mRNA (Ding et al., 2002).
Furthermore, RNAi-mediated downregulation of U2AF35 in HeLa cells has been reported
to alter the ratios of alternatively spliced isoforms of transcripts encoding the oncogenic
Cdc25B phosphatase, and to increase the level of Cdc25B protein (Pacheco et al., 2006b).
In conclusion, there is a growing list of splicing factors that have been found to be up- or
down-regulated in cancers, as compared to the corresponding normal tissues. Nevertheless,
in many cases, the available data are limited to correlations. A challenge for the future will
be to determine whether these changes are directly contributing to the cancer phenotype,
or they merely represent one of the multiple processes that are altered in cancer cells.
A critical issue is whether cells expressing abnormal levels of certain splicing factors are
positively selected for during tumour progression, as misregulated splicing factors may
induce production of splice variants that encode protein isoforms with advantages such as
increased proliferation, anti-apoptotic or pro-angiogenic effects, enhanced cell motility or
tumor cell survival. Moreover, many RNA-binding proteins are multifunctional and their
abnormal expression may have oncogenic effects that are independent from splicing. Also
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unknown is what triggers the up- and down-regulation of splicing proteins. Consistent
with the view that cancer-associated genetic instability is likely to play an important role
in this process, over-expression of splicing factor SF2/ASF was shown to associate with
amplification of the gene encoding for it (Karni et al., 2007), whereas reduced expression
of RBM5 in lung cancer correlates with deletion of its gene locus at chromosomal region
3p21.3 (Oh et al., 2006). Alternatively, or additionally, splicing factor transcripts appear
to be preferential targets for disrupted splicing in cancer tissues (Kim et al., 2008; Ritchie
et al., 2008). Cancer-specific splicing factor isoforms could either alter the function of the
protein in the cell, or reduce its level due to the introduction of a premature stop codon
and nonsense-mediated decay of the mRNA.
3.4.2 Splicing factors and anticancer therapy
During the past 20 years, anticancer drug development has focused on targeted medicines
that are more specifically associated with tumour cells than conventional cytotoxic drugs.
Over 600 new agents are currently in the development pipeline in the hope of attain-
ing greater anticancer activity with fewer side effects (Dancey and Chen, 2006). Still at
the preclinical stage, several approaches are being explored for the correction of cancer-
associated splicing abnormalities (for a comprehensive review see Pajares et al. (2007);
Wang and Cooper (2007)). One strategy uses synthetically modified oligonucleotides that
are able to block spliceosome assembly at specific sites, thereby preventing the generation
of cancer-associated splice variants. This approach has been successfully used to shift
the ratio of antiapoptotic to proapoptotic proteins produced by alternative splicing of the
Bcl-x gene, thereby sensitizing refractory cancer cells to undergo apoptosis in response to
chemotherapeutic drug treatment (Taylor et al., 1999). Another strategy consists of rais-
ing antibodies against epitopes that are uniquely present in the cancer-associated protein
isoforms and conjugate the antibodies to tumour-cell toxins. For example, human recom-
binant antibodies specific to the alternatively spliced domains of tenascin-C large isoform,
an abundant glycoprotein of cancer extracellular matrix that is virtually undetectable in
normal adult tissues, show promising tumor-targeting properties (Brack et al., 2006).
Strategies for targeting components of the splicing machinery that are abnormally ex-
pressed in cancer are expected to be less specific because they are likely to impinge on
splicing regulation in normal cells. Nevertheless, many approaches have been attempted
with encouraging results. Particular attention has been devoted to the development of
protein kinase inhibitors that modulate the activity of splicing factors containing RS do-
mains, which are characterized by repeats of arginine-serine dipeptides. Phosphorylation/
dephosphorylation of these serine residues are thought to act as switches that modulate
the binding properties to both RNA and proteins (Singh and Valca´rcel, 2005). Although
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there are several known splicing factor kinases, members of the SRPK (SR protein kinase)
family appear to be the most relevant in cancer (see Table 1). Down-regulation of SRPK1
expression by siRNA in cancer cell lines caused a reduction of cell proliferation and in-
creased sensitivity to gemcitabine and cisplatin, making the approach of targeting SRPK1
a promising tool that may prove therapeutically effective for tumours that overexpress of
this protein (Hayes et al., 2006, 2007). In addition to kinases, aberrant expression of splic-
ing factors in tumour cells might be implicated in resistance to drugs commonly used in
cancer therapy. For example, increased expression of the splicing factors PTB and Srp20
in ovarian cancer correlates with the production of alternatively spliced isoforms of the
multidrug resistance protein 1 (mrp1) that confer increased resistance to doxorubicin (He
et al., 2004). Another splicing factor highly expressed in numerous carcinomas, SPF45
(RBM17), affects the alternative splicing of the apoptosis regulator Fas (Corsini et al.,
2007), and over-expression of SPF45 has been implicated in resistance to doxorubicin and
vincristine (Sampath et al., 2003).
It is fully anticipated that inhibiting the function of either a splicing kinase or a splicing
protein will have a pleiotropic effect by altering the splicing of numerous gene products in
both cancer and normal cells. However, a well-established principle of cancer therapy is
to use a combination of drugs with different mechanisms of action and resistance, at their
optimal doses and according to schedules that are compatible with normal cell recovery.
Thus, it may be possible to develop and optimize agents that temporarily inhibit a splicing
regulator and partially correct abnormal splicing, resulting in enhanced tumour cell killing
by chemotherapeutic drugs. Very recently, a proof of concept has been provided for the
development of anti-tumour compounds that target the splicing machinery. Spliceostatin
A (Kaida et al., 2007) and pladienolide (Kotake et al., 2007), two potent inhibitors of
cycling cancer cells, target the essential splicing protein SF3b and inhibit splicing of several
transcripts. Both drugs are only mildly toxic to animals and a pladienolide derivative,
E7107, has already progressed to clinical trials. This moderate toxicity is probably due to
partial inhibition of splicing throughout the organism, but why cancer cells are particularly
vulnerable to the drugs remains unknown. Most important, these studies have defined a
new mode of action in anticancer drugs and identified a ubiquitous core component of the
U2 snRNP, SF3b, as a valuable new therapeutic target.
In summary, the rapid development and increasing availability of novel genome-wide
tools will soon provide a catalogue of all splicing factors and all splice variants that are
differentially expressed in specific cancer types and the corresponding normal tissues.
Irrespectively of whether changes in splicing play a direct causative role in cancer, or
act as modifiers or susceptibility factors in the oncogenic process, the identification of
splicing signatures is likely to provide important markers for diagnosis, prognosis, and/or
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sensitivity to treatment. A full description of all components of the splicing machinery
and splicing events altered in cancer will also identify potential new targets for therapeutic
approaches. However, the most challenging goal for the future will be to integrate the
different layers of gene expression regulation altered in cancer and to acquire a systems
biology view of the multiple molecular mechanisms that contribute to the pathophysiology
of this disease.
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Chapter 4
Cancer-associated splicing
misregulation
The original work described in this chapter is in preparation for submission to a peer
reviewed journal.
I would like to stress that some of the results presented and discussed in this section
are the product of collaborative work. Ineˆs Mollet was responsible for the annotation of
exon-microarray probes according to ExonMine.
Keywords: alternative splicing; exon-microarrays; cancer; splicing regulatory se-
quences
Abstract: Alternative splicing generates a huge diversity of transcript variants and
disruption of splicing regulatory networks is emerging as a major contributor to various
diseases, including cancer. Disruption of alternative splicing in cancer cells occurs in
the absence of mutations in the affected genes and current evidence indicates that the
splicing machinery is a major target for misregulation in cancer. Here, we collected a
high-confidence set of misregulated splicing events for colon and lung cancers by apply-
ing a comprehensive workflow analysis to splicing-sensitive microarray data. Functional
analysis using distinct sets of genes split according to misregulation level revealed that
some pathways are more affected by variations in transcript abundance, whereas others
at alternative splicing level. We identified misspliced exons containing cis-acting RNA
elements obtained from CLIP-seq data for SF2/ASF, which is overexpressed in both can-
cers. The cancer-associated splicing events also contained enriched motifs that resemble
binding sites for additional cancer misregulated splicing factors.
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4.1 Introduction
Alternative splicing of precursor messenger RNAs (pre-mRNAs) is a mechanism by which
proteomic diversity is generated from a low number of genes. The number of human genes
subject to alternative splicing increased from >60% based on ESTs-based studies to 92-
95% in recent high-throughput sequencing technologies (Wang et al., 2008a; Pan et al.,
2008).
Pre-mRNA splicing is carried out by the spliceosome, a macromolecular complex
formed from several small nuclear ribonucleoprotein particles (snRNPs) and numerous
non-snRNP splicing factors (Jurica and Moore, 2003; Wahl et al., 2009). Specific se-
quences located at and near the 5′ and 3′ splice sites are recognized by the spliceosome,
triggering the splicing process. However, the splice site sequences are weakly conserved
and require additional regulatory sequences termed splicing enhancers and silencers lo-
cated in exons or introns (Maniatis and Tasic, 2002; Matlin et al., 2005). These additional
regulatory sequences are recognized by splicing factors, which are commonly classified as
splicing activators or repressors depending on whether they facilitate or suppress the as-
sembly of snRNPs onto splice sites. Thus, regulation of alternative splicing is mediated by
the cooperative binding of trans-acting splicing proteins to cis-acting sequence elements
in the pre-mRNA.
Disruption of alternative splicing has been associated with several diseases, including
cancer (Cooper et al., 2009). This disruption can be caused by several mutations affecting
the splicing of oncogenes, tumour suppressors and other cancer-relevant genes (Srebrow
and Kornblihtt, 2006; Venables, 2006). However, many splicing abnormalities identified in
cancer cells are not associated with mutations in the affected genes. Indeed, recent studies
suggest that changes in splicing factor expression may play a key role in the general splicing
disruption that occurs in many cancers.
Karni et al. (2007) showed that splicing factor SF2/ASF (SFRS1) is up-regulated in
various human tumours and affects alternative splicing of the tumour suppressor BIN1
and the kinases MNK2 and S6K1. Recent bioinformatics studies also suggest that splicing
factors are not expressed at proper levels and/or their functions are impaired in cancer
(Kirschbaum-Slager et al., 2004; Kim et al., 2008; Ritchie et al., 2008).
A large number of cancer-associated alternative splicing events have been identified by
several studies using splicing-sensitive microarrays. however, few associations between mis-
regulated splicing factors and splicing events in the same cancer were established (Relo´gio
et al., 2005; Gardina et al., 2006; Thorsen et al., 2008; Zhang et al., 2006; Thorsen et al.,
2008; French et al., 2007; Cheung et al., 2008; Xi et al., 2008; Soreq et al., 2008; Thorsen
et al., 2008). For example, Relo´gio et al. (2005) showed for Hodgkin lymphoma cells that
Nova2 was overexpressed and the expression was correlated with gene isoforms detected
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with splicing-sensitive microarrays.
More recently, using high-throughput RT-PCR, misspliced genes were identified in
ovarian and breast cancers, from which many contained binding-sites for FOX2 protein
(Venables et al., 2009). These authors also showed that FOX2 is down-regulated in ovarian
cancer and misspliced in breast cancer, leading to an overall depletion of FOX2 protein
and splicing modulation.
Here, we used splicing-sensitive microarray data to investigate associations between
changes in splicing factor expression and alternative splicing events in colon and lung
cancers.
4.2 Material and Methods
4.2.1 Microarray data collection and analysis
For identification of cancer-associated alternative splicing events Affymetrix GeneChip
Exon Microarray data sets were collected from previous studies for colon cancer (Gardina
et al., 2006) and lung cancer (Xi et al., 2008). Microarray data were analysed using
R and suitable packages available from CRAN (R Development Core Team, 2009) and
Bioconductor (Gentleman et al., 2004). The raw data for the Affymetrix GeneChip Exon
microarray data sets were normalized and summarized using the FIRMA method (Purdom
et al., 2008) implemented in aroma.affymetrix package (Bengtsson et al., 2008). The
statistical significance from the gene and exon expression alterations was assessed using
linear models and empirical Bayes methods (Smyth, 2004) implemented in the limma
package (Smyth, 2005). Graphical representation of Firma scores for each probeset or
probe selection region (PSR) was based on annotated exons from ExonMine (Mollet et al.,
submitted, http://imm.fm.ul.pt/exonmine/).
4.2.2 Functional and pathway analysis
Functional and pathway analysis was performed using four gene sets according to misreg-
ulation level: transcript; alternative splicing; only alternative splicing and no transcript
abundance variation; all misregulated genes at transcript or alternative splicing levels.
The entire list of genes present in the Affymetrix GeneChip Human Exon microarray were
used as control or reference set for all analyses.
The enrichment of biological functions was analysed using Ingenuity Pathway Analysis
software (Ingenuity Systems, Mountain View, CA, USA). Pathways significantly affected
were identified using the systems biology approach from Pathway-Express tool (Draghici
et al., 2007).
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4.2.3 Ab initio motif searches
The ab initio motif search was performed using the SeedSearcher algorithm (Barash et al.,
2001). This algorithm identifies sequence motifs that discriminate a set of query sequences
from a group of control sequences. Three groups of query sequences were defined for each
cancer: exons enriched in cancer samples (inclusion in cancer), exons enriched in normal
samples (exclusion in cancer), exons with splicing misregulated (inclusion or exclusion).
For the control group we selected exons without splicing variations between cancer and
normal tissue from genes with high overall gene expression in all samples (expressed genes).
The motif search covered the sequences for the alternative exon, 150 nucleotides of
intron sequencing flanking the misspliced exon and the neighboring exons. The first 10
and last 30 nucleotides of introns were excluded from all sequences as these contain con-
served signals for the constitutive splicing machinery. Only misspliced exons for which no
splicing variation in the neighbor exons was detected in cancer were used. Several Seed-
Searcher searches were performed using different motif length and with various degrees of
sequence flexibility (i.e., number of wildcards represent the possible number of degener-
ate nucleotides): 5 nt (zero and one wildcard), 6 nt (zero and one wildcard), 7 nt (zero,
one and 2 wilcards), 8 nt (one to 3 wildcards), 9 nt (2 to 3 wildcards) and 10 nt (2 to
4 wildcards). The motifs were ranked by the statistical significance score computed and
corrected for multiple hypotheses testing by SeedSearcher (Barash et al., 2001). To iden-
tify the enriched motifs with different frequencies between included and excluded exons in
cancer we used Fisher’s exact test (Fisher, 1935).
Statistically significant motifs were compared against a list comprising previously re-
ported motifs associated with splicing (Cartegni et al., 2003; Martinez-Contreras et al.,
2007; Gabut et al., 2008; Long and Caceres, 2009).
4.3 Results and Discussion
4.3.1 Workflow for the detection of alternative splicing
To identify misregulated splicing events in cancer, we analysed Affymetrix GeneChip Exon
Microarray data sets from previous studies for colon cancer (Gardina et al., 2006) and lung
cancer (Xi et al., 2008).
The Affymetrix GeneChip Human Exon 1.0 ST array can determine the expression
of virtually all exons present in human genome, deriving from annotations ranging from
highly curated mRNA sequences to ab-initio computational predictions (Gardina et al.,
2006). The array contains approximately 5.4 million probes grouped into 1.4 million
probesets or probe selection regions (PSR), for which 90% are represented by 4 probes. A
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PSR usually corresponds to one exon, however some exons can contain several PSRs.
For detection of alternative splicing and overall gene expression variation, we applied
and combined methodologies previously and successfully applied for pre-processing, sum-
marization, filtering and statistical analysis. Microarray quality, normalization and sum-
marization were assessed using the aroma.affymetrix package (Bengtsson et al., 2008).
Background correction and quantile normalization were applied using the entire set of
main-design probes.
After pre-processing, two different types of expression indexes were computed for each
gene: exon (represented by one or more probe selection region) and transcript levels. The
transcript levels correspond to the amount of molecules transcribed from a single gene
including various alternative splicing isoforms and it provides the baseline to compare
the individual exon expression. These indexes were estimated using the FIRMA method
(Purdom et al., 2008) implemented in aroma.affymetrix package. Briefly, the transcript
level of each sample is estimated by fitting an additive model for each gene and the iden-
tification of alternative splicing events is framed as a problem of outlier detection. Thus,
alternative spliced exons are identified by whether its probesets systematically deviate
from the expected transcript expression level and a FIRMA score is estimated for each
probeset. For the summarization we used the gene definitions from Ensembl (Hubbard
et al., 2007), where 332532 probesets were previously mapped to the Ensembl annotated
exons and corresponded to 23385 genes (Purdom et al., 2008).
To reduce false positive predictions of alternative splicing events, filtering steps were
applied to the data prior to statistical analysis. As has been noted in previous works (Gar-
dina et al., 2006; Purdom et al., 2008; Shah and Pallas, 2009) probesets with hybridization
levels close to background (unexpressed transcripts and/or exons spliced out in all sam-
ples) can induce false positives. We filtered out probesets and transcript summary values
that were found below the lower quartile of the intensity distribution for all samples (Shah
and Pallas, 2009). For alternative splicing detection we removed also the probesets that
hybridize at very high levels (saturated response), filtering out probesets with intensity
values found above the 90th percentile for all samples. Since the FIRMA methods detects
alternative splicing as deviation from the expected transcript expression, probesets close
to intensity saturation will result in a decrease in sensitivity for true splicing detection
(Bemmo et al., 2008).
We also re-annotate all microarray probes according to ExonMine database (Mollet
et al., submitted, http://imm.fm.ul.pt/exonmine/) and removed all the probesets that
perfectly match more that one region (co-hybridization). This database provides all splic-
ing patterns obtained from clustering spliced ESTs and mRNAs to protein coding genes
and detects a significantly higher percentage of spliced genes, isoforms and exons compared
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Table 4.1: Precision of workflow for alternative splicing events detection. Comparison
of the alternative splicing events (ASE) found in our analysis with the ASE validated in previous
exon-microarray studies using RT-PCR. The number of ASE and Precision (proportion of selected
ASE corresponding to True Positives) for our analysis and previous studies is also indicated.
Cancer Type Genes with ASE validated in Previous Studies Previous genes in our analysis
Reference Confirmed Nr. Precision Nr. Precision
colon Gardina et al. (2006) Yes 14 0,33 12 0,71
No 29 5
Thorsen et al. (2008) Yes 6 0,27 4 0,80
No 16 1
lung Xi et al. (2008) Yes 6 0,55 3 0,75
No 5 1
to other recently published alternative splicing databases.
After pre-processing and filtering, we assessed the fold-changes and respective statis-
tical significance for alterations at transcript and alternative splicing level between cancer
and normal samples using linear models and empirical Bayes methods (Smyth, 2004) im-
plemented in the limma package (Smyth, 2005). Transcript and alternative splicing alter-
ations were ranked according to B-statistics and a suitable B-value cut-off was selected by
visually inspecting the volcano plot, which compares biological significance (represented
by fold-changes) with statistical significance (B-values) (Jin et al., 2001). Additionally,
we verified the p-values corresponding to moderated t-statistics. Using the Benjamini and
Hochberg method (Benjamini and Hochberg, 1995), all transcript and alternative splicing
alterations selected as significant had adjusted p-values lower than 0.00005 for lung can-
cer and 0.05 for colon cancer. The higher p-values found for colon cancer are due to the
smaller number of samples and the heterogeneous stages of cancer progression as stated
in the original study (Gardina et al., 2006).
To overcome the problem of confounding multiple alternative splicing events with over-
all transcript variation (McKee et al., 2007), alternative splicing alterations from genes
presenting changes in transcript abundance and alternative splicing for 40% of the exons
were not considered for further analysis.
Finally, for visualization of results in the context of gene architecture, we graphically
displayed FIRMA scores and intensity values for all probesets and samples along the gene
using information from ExonMine (Figures 4.1 and 4.2). Positive FIRMA scores corre-
spond to exon enrichment (inclusion) in the transcript, whereas negative values represent
exon depletion (exclusion).
To evaluate the quality of the alternative splicing events selected we compared our
results with previous exon-microarray studies where validations were perfomed by RT-
PCR (Table 4.1).
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Figure 4.1: Example of alternative splicing event found in colon cancer. Graphical
representation of the ACTN1 gene showing mutually exclusive exons: inclusion of exon 19 and
exclusion of exon 19A in colon cancer (highlighted with *). The dots represent the log intensities
(bottom plot) and the FIRMA scores (top plot) for each probe set and each line corresponds to a
sample. The exons (constitutive exons - dark blue; alternative exons - light blue; new exons - green)
and introns (gray) for ACTN1 are displayed in the top plot according to ExonMine information.
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Figure 4.2: Example of alternative splicing event found in lung cancer. Graphical repre-
sentation of the CEACAM1 gene showing exclusion of exons 5A and 5B in lung cancer (highlighted
with *). The dots represent the log intensities (bottom plot) and the FIRMA scores (top plot) for
each probe set and each line corresponds to a sample. The exons (constitutive exons - dark blue;
alternative exons - light blue; new exons - green) and introns (gray) for CEACAM1 are displayed
in the top plot according to ExonMine information.
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In the original study from the colon cancer microarray data set 14 out of 43 genes were
confirmed by RT-PCR (Gardina et al., 2006). 12 of the validated genes were also selected
in our workflow (LGR5, ZAK, ACTN1, ATP2B4, CALD1, COL6A3, FN1, GK, MAST2,
TPM1, VCL), whereas only 5 from the 29 false positives appear in our list.
In another exon-microarray study using different colon samples, 6 of 23 splicing events
were confirmed (Thorsen et al., 2008) and 4 of the validated events were also selected in
our analysis (ACTN1, CALD1, COL6A3 and VCL). Based on this validation our results
only presented one (TPM1) of the 16 false positives. However this event was confirmed in
the study referred to above (Gardina et al., 2006).
For lung cancer microarray data set 6 out of 11 genes were confirmed in the original
study (Xi et al., 2008), from which 3 genes also presented splicing events in our analysis
(CEACAM1, ERG and RASIP1). However, we identified the upstream exon as being
alternatively spliced for ERG and RASIP1 when compared to the original study. Splicing
events were identified for several exons of these two genes in our analysis suggesting more
complex alternative splicing patterns.
FIRMA scores of alternative splicing events previously validated for ACTN1 in colon
(Gardina et al., 2006) and CEACAM 1 in lung cancer (Xi et al., 2008) are graphically
represented in Figures 4.1 and fig:CEACAM1.
Overall, these results indicate a higher precision from our workflow relative to previous
studies. Although we could not detect all previously validated alternative splicing events,
we should have a high confidence in our collection of alternative splicing events.
4.3.2 Cancer-associated misregulations at transcript and alternative splic-
ing level
Using the workflow described above we identified expression variation at transcript and
alternative splicing level for colon and lung cancer (Table 4.2 and Annex Tables A.3.1 -
A.3.4).
A lower number of misregulated genes at both levels were identified for colon relative
to lung cancer, but this can result from the modest sample size and the heterogeneous
stages of cancer progression as stated in the original study (Gardina et al., 2006). However,
colon cancer presented higher number of genes with changes only at alternative splicing
but no variation at transcript level. Thus, the majority of misregulated genes in lung
cancer undergo changes both in abundance and in transcript architecture.
Colon and lung cancers presented common misregulated genes at transcript and alter-
native splicing level (Table 4.2). The same misspliced exon was observed in both cancers
for 29 genes and eight genes present variations only at the alternative slicing level for
both cancers (COL6A3, MDK, AHNAK, JUP, PPP1R12B, SNTG2, CDCA7, CDH19).
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Table 4.2: Number of genes with variations at transcript and alternative splicing level
for colon and lung cancers. The number of genes with overall up or down-regulation is described
for each cancer type. The number of genes presenting alternative splicing events (ASE) but no
variation at trasncript level is also shown.
Number of genes: Colon Cancer Lung Cancer Common to Both Cancers
Differentially Expressed 560 1456 154
Up-regulated 418 527 99
Down-regulated 142 929 52
With ASE (Nr. of ASE) 467 (550) 791 (1308) 29 (38)
With ASE but no variation at gene level 330 223 8
Indeed, the misspliced exon identified for COL6A3 was recently found and validated for
colon, bladder and metastic prostate cancers (Thorsen et al., 2008). COL6A3 encodes a
protein of the extracellular matrix and the included exon 6 in cancer most likely contains
several predicted phosphorylation sites, which have potential regulatory effects on protein
function (Thorsen et al., 2008). Moreover, these authors found three genes with common
misregulated exons for colon, bladder and prostate cancers using exon arrays, which al-
ternative splicing events were also detected in our results for colon cancer (CALD1,VCL
and ACTN1). The previously reported results showed a clear relationship between ad-
vanced cancer stage and systematic occurrence of alternative splicing isoforms, suggesting
that some of the identified splice variants could be driving forces in cancer development
(Thorsen et al., 2008).
Similarly to COL6A3, our results suggest that the cancer-misregulated splicing events
identified by our approach may affect protein function. According to Ensembl annotation
(Hubbard et al., 2007) approximately 75% of the alternative splicing events found for colon
and lung cancers were located inside the coding sequence and from which 40% most likely
encode protein domains (Annex Tables A.3.3 and A.3.4).
Next, we asked whether the different sets of genes misregulated at the transcript and
alternative splicing levels in cancer belong to different functional categories. The genes
were split in four groups according to misregulation level: transcript; alternative splicing;
only alternative splicing and no transcript abundance variation; all misregulated genes at
transcript or alternative splicing levels.
Functional analysis using Ingenuity Pathway Analysis software (Ingenuity Systems,
Mountain View, CA, USA) showed cancer and genetic disorder (also includes cancer) as
the top first associated diseases for both cancers and all sets of genes (Benjamini-Hochberg
adjusted p-value < 0.05) (Annex Table A.3.5 and A.3.6). Roughly 30% of the misregulated
genes were associated with cancer disorder. Gastrointestinal disease also appeared as a top
disease for all sets of genes in colon cancer (Benjamini-Hochberg adjusted p-value < 0.05).
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Similar enrichment was found for both cancer types in molecular and cellular functions
with top first corresponding to: cell cycle, cell death, cellular growth and proliferation
(Annex Table A.3.5).
We next identified pathways that were significantly affected by applying the systems
biology approach from Pathway-Express tool (Draghici et al., 2007). This method includes
the classic statistical features of gene set enrichment analysis but also considerers other
factors such as the magnitude of the expression changes of each gene, the position of the
genes on the given pathways, the topology of the pathway that describes how these genes
interact, and the type of signaling interactions between them. The method estimates an
impact factor for each pathway, which corresponds to the negative log of the global prob-
ability of having both a statistically significant number of misregulated genes and a large
perturbation in the given pathway. Since we could not determine the final variation for
genes affected at splicing level, we performed the analysis without considering expression
fold-changes.
Figure 4.3 shows the top enriched pathways according to the impact factor for each
cancer type and misregulation level (False discovery rate adjusted p-value < 0.05) (Annex
Tables A.3.5 and A.3.6). The majority of affected pathways were previously associated
to cancer (Weinberg, 2007) and although some pathways contained misregulated genes at
transcript and alternative splicing levels, a significant enrichment was only observed for
some gene sets. So, most pathways appeared to be differentially affected by variations in
transcript abundance or architecture. Extracelullar matrix receptor was the only pathway
for which an enrichment was observed for all groups of genes, thus suggesting a high impact
of changes at both levels for the component genes.
Pathways related to cell growth and death (cell cycle, p53-signaling) and replication
and repair of genetic information (DNA replication, mismatch repair and nucleotide exci-
sion repair) were significantly impacted by variations of transcript abundance in colon can-
cer. In contrast, alternative splicing alterations appear to affect other pathways, namely:
cell motility (regulation of actin cytoskeleton), immune system (Toll-like receptor signaling
pathway, leukocyte transendothelial migration), cell communication (including adherens
juntion, gap junction and tight junction).
Since the majority of misspliced genes in lung cancer also present changes at transcript
abundance only two pathways appeared significantly affected by genes with changes only
at alternative splicing level: extracellular matrix receptor and cell communication.
Alterations in transcript diversity for lung cancer affect also pathways related to sig-
naling molecules and interaction (ECM-receptor interaction, cell adhesion molecules), sig-
naling transduction (TGF-beta signaling pathway), cell motility (regulation of actin cy-
toskeleton) and cell communication (including adherens juntion, gap junction and tight
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Figure 4.3: Biological pathways associated with cancer misregulated genes. Top path-
ways significantly impacted based on Pathway-Express (fdr adusted p-value < 0.05) for colon and
lung cancer splitting genes according to misregulation level: transcript; alternative splicing; only
alternative splicing and no transcript abundance variation; all misregulated genes at transcript or
alternative splicing levels. The gradient color corresponds to the Impact Factor. The row colors
identify pathways for the same biological category. More details in Annex Tables A.3.5 and A.3.6.
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junction).
Both cancers appeared to be significantly affected by changes in transcript architec-
ture from genes associated to cell communication. However only two misspliced genes
were shared between the two cancers (COL6A3 and FIN1). Similarly, regulation of actin
cytoskeleton appeared to be significantly affected by variations at the alternative splic-
ing level but only four misspliced genes were common to both cancers (MYLK, FN1,
PPP1R12B, IQGAP3). Association of misregulated splicing in colon, bladder and prostate
cancers with regulation of actin cytoskeleton was described in previous genome-wide stud-
ies (Gardina et al., 2006; Thorsen et al., 2008). Remodeling of actin cytoskeleton is
fundamental in proliferation, apoptosis, cell invasion and metastasis (reviewed in Hall,
2009).
Our results also suggest that common cancer-related pathways are misregulated at
different levels. Genes associated to MAPK signaling pathway, leukocyte transendothelial
migration, gap junction and tight junction are mostly affected by changes in transcript
abundance for lung cancer, whereas in colon cancer alternative splicing has a higher impact.
Indeed, a gene from MAPK signalling pathway, ZAK, is down-regulated in lung cancer
and misspliced in colon cancer.
Moreover, we could also identify pathways for which genes are misregulated at tran-
script and alternative splicing level but the enrichment is only significant when combining
the two gene sets (Wnt-signaling pathway and biosynthesis of unsaturated fatty acids for
colon cancer, and Glycan structures-biosynthesis for lung cancer).
These results highlight the importance of including information of the several layers of
gene expression regulation on functional and pathway analysis.
4.3.3 Misregulated splicing factors
Colon cancer presented few misregulated splicing factors, corresponding mostly to snRNP
associated proteins overexpressed in cancer (PRPF6, SF3B3, SNRPG) or with alternative
splicing events (PRPF8, SF3B2). Other splicing factors, like HNRNPC and NONO also
presented alternative splicing events. However, no splicing factors were found in common
between Exon and 3′ microarray analysis from the previous chapter (Section 3.3.1 and
Figure 4.4a).
For lung cancer few overall gene expression variations of splicing regulatory genes were
also found, with only one up-regulated gene (SRPK1) and three down-regulated genes
(CUGBP2, ZRSR1, SFRS5). Comparing the two microarray platforms only SRPK1 and
CUGBP2 were detected in common. The majority of the splicing-related genes from 3′
array analysis presented smaller fold-changes in exon arrays, which were not sufficient to
be considered as differentially expressed (Section 3.3.1 and Figure 4.4b). We could also
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(a) Colon Cancer
(b) Lung Cancer
Figure 4.4: Common splicing-related genes between exon and 3′ microarrays.
Splicing-related genes with overall gene expression variations using different microarray platforms
Affymetrix 3′ and Exon microarrays for (a) colon and (b) lung cancers.
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detect alternative splicing events in lung cancer for CUGBP2 , NOVA2 and SFRS12 genes.
The few misregulated splicing factors detected by both platforms could be due to cancer
samples heterogeneity (differences in tumor subtypes) or to differences in the array design
(number and distribution of the probes along the gene) as previously observed (Robinson
and Speed, 2007).
4.3.4 Splicing factors associated with cancer-associated alternative splic-
ing events
SF2/ASF (SFRS1) protein overexpression was already described for several cancers, in-
cluding lung (Karni et al., 2007) and colon cancers (Ghigna et al., 2005). Recently, Sanford
et al. (2009) used CLIP-seq to identify cis-acting RNA elements recognized by SF2/ASF.
Using this CLIP-seq data we found SF2/ASF target regions in 61 (5%) misspliced exons
for colon and 55 (10%) for lung cancers (Figure 4.5 and Annex Tables A.3.9 and A.3.10).
SF2/ASF target regions were equally distributed between inclusion and exclusion alterna-
tive splicing events.
Since alternative splicing can also involve regulatory sequences located in flanking
regions (Ule et al., 2006; Martinez-Contreras et al., 2006; Fagnani et al., 2007; Wang et al.,
2008a), we extended our search to the flanking introns and neighboring exons from the
misspliced exon. Thus, a total number of 87 (7%) misspliced exons in colon and 97 (17%)
in lung cancers contained SF2/ASF binding sites in the alternative exons and flanking
regions (Figure 4.5 and Annex Tables A.3.9 and A.3.10). SF2/ASF CLIP-seq targets were
observed across all neighboring regions and some alternative splicing events contained
targets in multiple regions. From the 29 misspliced genes shared between both cancers
only six genes seem to be targeted by SF2/ASF, corresponding all to exclusion events with
different binding site distribution: alternative exon (DMN, H3F3B, SLC2A1, HDLBP),
downstream adjacent intron and exon (CDCA7), both neighboring exons (TPX2). The
distribution of the SF2/ASF binding sites across the several regions was similar for enriched
and depleted exons. However, SF2/ASF may regulate inclusion or exclusion through the
binding of adjacent constitutive exons (Ghigna et al., 2005). Indeed, Sanford et al. (2009)
observed an enrichment of SF2/ASF binding sites in neighboring exons of alternative
cassette exons. They proposed that SF1/ASF may play a prominent role in regulating
this mode of competitive exon skipping by activating downstream splice sites. Moreover,
the inclusion and exclusion of an exon results from the combination and balance of multiple
interactions between splicing factors and regulatory sequences present in the alternative
exon and adjacent flanking regions, including introns and neighboring exons.
Similar to Sanford et al. (2009), we observed that SF2/ASF candidate targets are
enriched (Ingenuity Pathway Analysis, Benjamini-Hochberg adjusted p-value < 0.05) for
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Figure 4.5: Misspliced genes in colon and lung cancers containing CLIP-seq blocks for
SF2/ASF (SFRS1). For each alternative splicing event (ASE) is indicated the type (inclusion
or exclusion) and the location of the CLIP-seq block: upstream exon, upstream intron, alternative
exon, downstream intron, downstream exon. More details in Annex Tables A.3.9 and A.3.10.
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genes encoding proteins involved in gene expression (12% for lung and 15% for colon
cancers) and RNA post-transcriptional modification (7% for colon cancer).
SF2/ASF CLIP-seq targets were not found for the majority of mispliced exons, but
this can be explained by the fact that CLIP-seq data was obtained from embryonic kidney
cells (HEK293T), not expressing a gene pool similar to colon and lung. Thus, we used
the previously described consensus Position Weight Matrix (PWM) for SF2/ASF based
on CLIP-seq data (Sanford et al., 2009) to find more candidate misregulated exons. Ap-
proximately 65% of the misspliced exons of each cancer contained a putative binding site
based on the PWM (scores above the matching score threshold of 5.2) for SF2/ASF in
the alternative exon region and the target exons increased to 99% when considering the
flanking introns or neighboring exons. We did not observe a correlation between the event
type and the wide distribution of putative binding sites.
We also verified whether the cancer-associated splicing events could share more com-
mon regulatory sequences performing a motif enrichment analysis using the SeedSearcher
algorithm (Barash et al., 2001). We searched for motifs that would best discriminate mis-
spliced exons in cancer from exons with no splicing variation between cancer and normal
tissue. The misspliced exons were grouped in exons enriched in cancer samples (inclusion
in cancer), exons enriched in normal samples (exclusion in cancer), exons with splicing
misregulated (inclusion or exclusion). Our search covered the sequences for the misspliced
exon, neighboring exons and 150 nucleotides of intron sequencing flanking the exons. Only
misspliced exons for which no splicing variation in the neighboring exons was detected in
cancer were used, corresponding to 275 exons for colon cancer (90 excluded and 185 in-
cluded) and 467 exons for lung cancer (238 excluded and 229 included). Each ab initio
search was performed for motifs with length from five to 10 nucleotides and with various
degrees of sequence flexibility as previously used by Fagnani et al. (2007).
We found 29 motifs enriched in misspliced exons for colon cancer and 559 for lung
cancer (Figure 4.6 and Annex Tables A.3.11 and A.3.12). The difference between the
two cancers could be related with the number of alternative splicing events used. Some
enriched motifs were common to several regions. Using Fishers’ exact test (Fisher, 1935) we
selected motifs with different frequencies (p-value < 0.05) between included and excluded
exons in cancer: 18 motifs for colon cancer and 145 for lung cancer (Figure 4.6 and Annex
Tables A.3.11 and A.3.12). Some differentially represented motifs were only enriched when
using all misspliced exons independently of event type (inclusion or exclusion). Also, some
motifs found using the set of all misspliced exons appeared enriched when using only the
subset of exons from the same event type.
The number of motifs was slightly higher for colon cancer in the flanking introns regions
than in misspliced exon and neighboring exons regions. For lung cancer the highest number
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(a) Colon Cancer
(b) Lung Cancer
Figure 4.6: Number of motifs enriched in cancer-associated alternative slicing events.
Number of enriched motifs found for each region of misspliced exons grouped according to event
type: exons enriched in cancer samples (inclusion), exons enriched in normal samples (exclusion),
exons with splicing misregulated (inclusion and exclusion). Gray bars indicate the enriched motifs
with non-discriminative frequencies (Fisher’s test p-value > 0.05) between exlcusion and inclusion
alternative splicing events. 84
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of total motifs was found in the neighboring exons, whereas the discriminating motifs were
found in more abundance in the flanking introns and misspliced exon. Interestingly, the
uspstream intron regions presented higher and differential number of discriminating motifs,
with more motifs in the 5′ region for exclusive events and in the 3′ region for inclusive
events. Moreover, all discriminate motifs found in the alternative exon region revealed
higher frequencies in inclusive events (Figure 4.6).
We compared the enriched motifs against a list comprising previously reported regula-
tory sequences associated with splicing (Cartegni et al., 2003; Martinez-Contreras et al.,
2007; Gabut et al., 2008; Long and Caceres, 2009). We identified some motifs that con-
tained or were part of described motifs and could resemble binding sites for splicing factors.
However the frequency of the original binding site sequence was similar in depleted and
enriched exons. Nevertheless, we could identify some cancer-associated splice variants
which can be potentially regulated by splicing factors with gene expression affected in the
same cancer.
Alternative exons excluded in colon cancer were enriched with the motif “GGGNC-
NCC” and the frequency of the motif in sequences of excluded events (23%) was signif-
icantly higher than in sequences of inclusion (1%) and control (8%). This motif con-
tains part of the motif described for HNRNPF, HNRNPH1, HNRNPH2 and HNRNPH3
(GGGA, GGGG). Indeed, using a stricter motif “GGGRNCNCC” (R denotes A or G) the
frequencies in excluded events (13%) were also higher than in included events (1%). While
no misregulation was found for these genes in our microarray analysis, previous studies
showed overexpression of HNRNPF at protein level in colon cancer (Balasubramani et al.,
2006). These results suggest that the up-regulation of HNRNPF in colon cancer can be
responsible for missplicing of some exons.
For lung cancer, the upstream intron 3′ sequence was enriched with the motif “AC-
NNAGG” and the frequency of the motif in sequences of excluded events (18%) was
significantly higher than in sequences of inclusion (8%) and control (10%). Two motifs
for antagonistic factors match the last part of the motif for SFRS5 (“ACDGS”, D denotes
A, T or G; S denotes G or C) and HNRPA1 and HNRPA2B1 (TAGG). Our microarray
analysis detected SFRS5 down-regulation in exon arrays and HNRPA2B1 up-regulation
in 3′ arrays. Moreover, overexpression of HNRPA1 and HNRPA2B1 at protein level was
previously described (Patry et al., 2003; Zhou et al., 1996). Since the SR (ACDGS) and
hnRNP (TAGG) sequences do not resemble each other, this suggest two different regu-
lation systems for exon exclusion by absence of SFRS5 and overepxression of HNRPA1
or HNRPA2B1. However, the frequencies of these two motifs in the excluded events was
slightly higher (43% for SR and 25% for hnRNP motif) than for the included sequences
(38% for SR and 22% for hnRNP).
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The splicing factor binding site sequences are often degenerate and lack sufficient
specificity to reveal the global organization of protein-RNA interactions. CLIP-seq or
splicing factor depletion approaches allow us to restrict targets containing a functional
binding site from a non-functional one. Sanford et al. (2009) observed that statistically
significant SF2/ASF binding sites (with scores above the matching score threshold for the
consensus PWM) could not be found for some of the SF2/ASF CLIP-seq blocks. Recently,
Venables et al. (2009) also observed that after FOX2 depletion only 87 out of 810 cassette
exons, containing at least one nearby FOX2 binding site, presented a shift in splicing
by more than 10% on average in ovarian and breast cancer cell lines. Only combining
information from more specific assays (CLIP-seq, splicing factor depletion, etc) for all
splicing factors will be possible to understand the alternative splicing code that controls
and coordinates the transcriptome in cancer.
4.4 Conclusion
Here we collected a high-confidence set of misregulated splicing events in cancer by ap-
plying a comprehensive workflow analysis to Affymetrix Exon Microarray data sets from
previous studies for colon (Gardina et al., 2006) and lung cancers (Xi et al., 2008).
Our approach revealed a different number of misspliced genes from the original studies.
We increased the number of misspliced genes previously identified for colon cancer, whereas
for lung cancer results our approach revealed to be more conservative, selecting less genes.
Nevertheless, the comparison of our results with previous validations by RT-PCR for these
cancers (Gardina et al., 2006; Thorsen et al., 2008; Xi et al., 2008) showed less false positive
events, corresponding to a higher precision of our methodology.
Functional analysis revealed that 30% of the misregulated genes at transcript and
alternative splicing levels and cancer types were previously associated with cancer disorder.
We found different enriched pathways when using distinct sets of genes split according to
misregulation level. The results may suggest that some pathways are more affected by
variations in transcript abundance, whereas others at alternative splicing level. Most of
the misspliced genes encoded for proteins associated with cell communication and motility,
signal transduction and signaling molecules and interaction. Our results highlight the
importance of including information of the several layers of gene expression regulation
on functional and pathway analysis. Although differences in transcript abundance have
routinely been used for gene expression profiling, it is clear that both the amount and the
sequence diversity of transcripts have a high impact in cancer.
We have also identified cancer-associated splice variants which are likely to be regulated
by splicing factors with gene expression affected in the same cancer. Overexpression of the
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splicing factor SF2/ASF (SFRS1) was recently observed in various human tumours and
shown to affect alternative splicing of both tumour suppressor genes and oncogenes (Karni
et al., 2007). Using SF2/ASF CLIP-seq data previously published (Sanford et al., 2009)
we found SF2/ASF binding sites for 87 (7%) misspliced exons in colon and 97 (17%) in
lung cancers, located either in the alternative exon, flaking introns or neighboring exons.
However, an association between alternative splicing decision and location of SF2/ASF
binding sites could not be established. The cancer-associated splicing events also con-
tained enriched motifs that match predicted binding sites for cancer misregulated splicing
factors, such as HNRNPF, SFRS5, HNRPA1 and HNRPA2B1. However, identification of
functional cis-acting RNA elements on a global scale is required to validate bioinformatic
predictions.
Our finding that specific pathways are commonly affected by splicing misregulation in
distinct cancers strengthens the view that splicing plays an important role in oncogenesis.
In some cases, the altered splicing events correlate with abnormal levels of regulatory
splicing factors that are expressed in the same tumours.
The rapid development and increasing availability of novel genome-wide tools will
soon provide a catalogue of all splicing factors and all splice variants that are differentially
expressed in specific cancer types and the corresponding normal tissues. Future stud-
ies will have to combine transcriptomic data with complementary approaches (namely,
Chip/CLIP-seq and proteomics) to to improve our understanding of how gene expression
regulatory networks are altered in cancer.
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Chapter 5
Final Remarks and Future
Perspectives
The present study aimed to generate microarray-based predictions for understanding the
alternative splicing code that controls and coordinates the transcriptome.
We systematically assessed the widespread gene expression of splicing regulators dur-
ing cell differentiation, in differentiated tissues and in cancer. By using large-scale data
analysis we revealed new differential expression of several splicing-related genes, which en-
coded proteins may modulate cell type or tissue specific alternative splicing. Moreover, our
work provided more evidences for the link between changes in splicing factors expression
and alternative splicing profiles. First, our splicing factor signatures for tissues correlated
with tissue-specific splicing events. Second, we identified cancer-associated splice variants
which seem to be regulated by splicing factors with gene expression affected in the same
cancer.
These results indicate the power of using microarray technology and computational
approaches to generate initial predictions for a global view of alternative splicing regula-
tion.
Furthermore, the large number of splicing-related genes with differential expression
found in the present study raises the question of whether changes in the expression level
of splicing factors regulate specific alternative splicing events that play key roles in cell
differentiation and cancer. The present work has made important and original scientific
contributions to solve these relevant but still open questions.
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Which splicing factors may influence alternative splicing patterns in a
highly specific manner?
The current hypothesis for differential alternative splicing regulation between tissues or
development stages suggests that differences in relative abundances or activities of multiple
proteins influence specific splicing decisions (Hanamura et al., 1998; Singh and Valca´rcel,
2005). Moreover, changes in the relative expression or cellular distribution of antagonizing
factors could establish a combinatorial code (Singh and Valca´rcel, 2005).
Previous gene-by-gene studies addressed the differential specificity of splicing factors,
focusing mainly on SR and hnRNP proteins (reviewed in Singh and Valca´rcel, 2005; Long
and Caceres, 2009). However, additional studies described other splicing factors inducing
specific splicing (reviewed in Singh and Valca´rcel, 2005), for example, ELAVL proteins
in mouse brain (Lisbin et al., 2001; McKee et al., 2005), A2bp1 (also known as FOX1)
in heart and brain (Shibata et al., 2000; Kiehl et al., 2001; Jin et al., 2003b), NOVA1 in
mouse brain (Ule et al., 2005).
Here, we systematically assessed the widespread expression of genes encoding several
splicing-related proteins. Using large-scale data we monitored their gene expression vari-
ations on different stages of myotube, adipocyte, erythroid and sperm cell differentiation
and also on tissues derived from human, chimpanzee and mouse. We identified over 100
splicing-related genes that are most highly differentially expressed in a particular tissue or
differentiation process. Our results showed that all genes of the main splicing factor fami-
lies present differential gene expression including SR protein kinases and snRNP proteins.
These results extended the list of splicing-related genes with differential gene expression,
corresponding to putative regulators for cell type or tissue specific alternative splicing.
Clearly, a major task for the future will be to determine whether tissue-specific alter-
native splicing events are regulated by the differential expression of the genes identified in
our study.
In the present work we also showed that splicing factor signatures correlate with tissue-
specific alternative splicing patterns. The largest number of tissue-specific splicing factor
genes was found for brain and testis, the two tissues for which highest levels of alternative
splicing events were previously found based on genome-wide studies using ESTs (Yeo et al.,
2004) and splicing microarrays (Pan et al., 2004; Clark et al., 2007).
Splicing microarrays have been recently developed and used for genome-wide analysis
of alternative splicing. Combining splicing microarrays and computational analysis se-
quence motifs were found that resemble splicing factor binding sites and correlate with
tissue-specific alternative splicing in mouse brain and muscle (Sugnet et al., 2006; Fagnani
et al., 2007) and human muscle (Das et al., 2007). In addition, several studies combin-
ing siRNA-mediated knockdowns or conventional knockouts of splicing factors and splic-
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ing microarray analyses revealed alternative exons regulated by specific splicing factors:
dASF/SF2, B52/SRp55, hrp48, and PSI in fruit fly (Blanchette et al., 2005); NOVA pro-
teins in brain mouse (Ule et al., 2005); PTB and nPTB in mouse neuronal differentiation
(Boutz et al., 2007) hnRNP L in mammals (Hung et al., 2008).
Furthermore, recent studies combining the annotation of binding sites with alternative
splicing patterns from splicing microarrays or high-throughput sequencing identified RNA
maps for the splicing proteins NOVA (Ule et al., 2006; Licatalosi et al., 2008) and FOX
(Zhang et al., 2008; Yeo et al., 2009). These RNA maps define the regulatory networks of
alternative splicing and can be used to predict the outcome of alternative splicing in other
genes.
Indeed, an important goal is to understand the splicing code and generate predictions
for cell-type and tissue-specific splicing patterns. To achieve this, future studies will have
to define cell-type and tissue-specific splicing regulatory motifs and how they function in
conjunction with each other as well as with the more generally used enhancer and silencer
motifs.
Which splicing factors may lead to splicing disruption in cancer?
Alternative splicing is associated with multiple human diseases including cancer (reviewed
in Wang and Cooper, 2007; Cooper et al., 2009). Several mutations are known that affect
the splicing of oncogenes, tumour suppressors and other cancer-relevant genes (Srebrow
and Kornblihtt, 2006; Venables, 2006), however, many splicing abnormalities identified in
cancer cells are not associated with mutations in the affected genes. Rather, a growing
body of evidence indicates that the splicing machinery is a major target for misregulation
in cancer.
Punctual cases of cancer misregulated splicing factors and connection to splicing dis-
ruption in cancer were previously described for SR, hnRNP and other regulators (see
Section 3.4.1). Interestingly, it was recently shown for the first time that over-expression
of a splicing factor can indeed trigger malignant transformation (Karni et al., 2007). The
authors showed that the splicing factor SF2/ASF (SFRS1) is up-regulated in various hu-
man tumours and affects alternative splicing of tumour suppressor and oncogenic genes
(Karni et al., 2007). This study serves as a proof-of-principle and shows that abnormally
expressed splicing proteins can have oncogenic properties.
Recent bioinformatics studies also suggest that splicing factors are not expressed at
proper levels and/or their functions are impaired in cancer (Kim et al., 2008; Ritchie et al.,
2008).
Here, we performed a large-scale analysis of expression profiles for several splicing
factors in 13 cancer types: bladder, brain, breast, colon, esophagus, head and neck, kidney,
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liver, lung neuroblastoma, prostate, thyroid and vulva. We have identified 192 splicing-
related genes that are differentially expressed in specific cancer types and the corresponding
normal tissues. These genes encoded the major splicing protein families snRNPs, hnRNPs,
SRs, SR-kinases, RNA-helicases-like and other splicing regulators. We also observed that
the majority of differentially expressed splicing regulators were up-regulated in cancer and
some misregulations appear consistently in several cancer types.
Consistent gene expression variations of splicing factors in several cancer was also
showed for SF2/ASF (SFRS1) for various human tumours (Karni et al., 2007). Thus
suggesting that some cancers can present common misregulated splicing factors.
Our results are also consistent with other analysis using on serial analysis of gene ex-
pression (SAGE) and Oncomine (microarray based information) that observed differential
expression for splicing factors in four cancer types (breast, colon, prostate and brain) and
over-expression was a general trend (Kirschbaum-Slager et al., 2004).
Furthermore, we showed a correlation between changes in splicing factor expression
and splicing events in the same cancer. We collected a high-confidence set of misregu-
lated splicing events in cancer by applying a comprehensive workflow analysis to splicing
microarray data sets from previous studies for colon and lung cancers. We identified mis-
spliced exons containing cis-acting RNA elements obtained from CLIP-seq data (Sanford
et al., 2009) for SF2/ASF, which is overexpressed in both cancers. We were also able
to identify motifs enriched in the cancer-associated splicing events that resemble binding
sites for cancer misregulated splicing factors.
A large number of cancer-associated alternative splicing events have been reported in
several studies using high-throughput technologies (Relo´gio et al., 2005; Gardina et al.,
2006; Thorsen et al., 2008; Zhang et al., 2006; Thorsen et al., 2008; French et al., 2007;
Cheung et al., 2008; Xi et al., 2008; Soreq et al., 2008; Thorsen et al., 2008). However, there
is scarce information on associations between misregulated splicing factors and splicing
events in the same cancer. Relo´gio et al. (2005) showed for Hodgkin lymphoma cells that
Nova2 was overexpressed and the expression was correlated with gene isoforms detected
with splicing microarrays. Recently, Venables et al. (2009) using high-throughput RT-
PCR identified misspliced genes in ovarian and breast cancers, from which many contained
binding-sites for FOX2 protein. They also showed that FOX2 is down-regulated in ovarian
cancer and misspliced in breast cancer, leading to an overall depletion of FOX2 protein
and splicing modulation.
The rapid development and increasing availability of novel genome-wide tools will soon
provide a catalogue of all splicing factors and all splice variants that are differentially ex-
pressed in specific cancer types and the corresponding normal tissues. Irrespective of
whether changes in splicing play a direct causative role in cancer, or act as modifiers or
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susceptibility factors in the oncogenic process, the identification of splicing signatures is
likely to provide important markers for diagnosis, prognosis, and/or sensitivity to treat-
ment (see Section 3.4.2 Splicing factors and anticancer therapy). A full description of
all components of the splicing machinery and splicing events altered in cancer will also
identify potential new targets for therapeutic approaches.
Role and future of high-throughput technologies in alternative splicing
The emergence and development of high-throughput technologies over the last two decades
has deeply modified our way of performing biological research, moving from a gene-by-
gene approach to global or genome-wide studies. These technologies revealed to have a
key role for the global view of alternative splicing regulation (reviewed in Lee and Roy,
2004; Blencowe, 2006; Ben-Dov et al., 2008; Hartmann and Valca´rcel, 2009)
The first genome-wide studies on alternative splicing relied on alignments of expressed
sequence tags (ESTs) and cDNA sequences to the genome and described alternative splice
forms in a surprisingly large fraction of human genes, ranging from 40% to 60% (Mironov
et al., 1999; Brett et al., 2000; Croft et al., 2000; Lander et al., 2001; Kan et al., 2001;
Modrek et al., 2001). Using this approach several large databases of alternative splicing
events were developed for several species: Intronerator (Kent and Zahler, 2000), ISIS
(Croft et al., 2000), TAP (Kan et al., 2001), HASDB (Modrek et al., 2001), ASAP (Lee
et al., 2003a), ProSplicer (Huang et al., 2003), ASD (Thanaraj et al., 2004), FASTDB
(de la Grange et al., 2005), ASPIC (Bonizzoni et al., 2005), MAASE (Zheng et al., 2005),
EuSplice (Bhasi et al., 2007), ExonMine (Mollet et al., submitted). However, ESTs/cDNA
analysis have some limitations (reviewed in Modrek and Lee, 2002), which have been
overcome by the development of microarray technology.
Microarray technology evolution has allowed us to resolve exon-level gene expression
and enabled large-scale profiling of mRNA splicing (reviewed in Blencowe, 2006). Several
splicing microarray platforms were developed consisting essentially in two types of ap-
proaches: exon and exon-junction centric platforms. The two approaches present distinct
advantages in their ability to measure transcript structure due the location of the probes.
The exon-centric platforms are more appropriate to identify novel splicing events since
probes are designed for well-annotated and predicted exons, whereas with exon-junction
platforms transcript architecture directly targeting pre-determined arrangements of exons
can be assessed (reviewed in McKee and Silver, 2007).
These platforms have permitted the discovery of new alternative splicing events, in-
creasing the number of affected genes to > 80% (Johnson et al., 2003; Kampa et al., 2004).
Several studies using splicing microarrays identified cell type and tissue-specific alternative
splicing profiles (Clark et al., 2002; Yeakley et al., 2002; Johnson et al., 2003; Wang et al.,
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2003; Le et al., 2004; Pan et al., 2004; Stolc et al., 2004; Watahiki et al., 2004; Srinivasan
et al., 2005; Nagao et al., 2005; Shai et al., 2006; Sugnet et al., 2006; Clark et al., 2007;
Ip et al., 2007; Hartmann et al., 2009). In addition, analysis of several mouse tissues
revealed that tissue-specific mechanisms of transcription and alternative splicing operate
on different subsets of genes (Pan et al., 2004).
Splicing sensitive microarrays allowed also the identification of new alternative splic-
ing events misregulated in Hodgkin lymphoma cells (Relo´gio et al., 2005), colon cancer
(Gardina et al., 2006; Thorsen et al., 2008), prostate cancer (Li et al., 2006; Zhang et al.,
2006; Thorsen et al., 2008), brain cancer (French et al., 2007; Cheung et al., 2008), lung
cancer (Xi et al., 2008) MG-thymona (Soreq et al., 2008), bladder cancer (Thorsen et al.,
2008).
As referred above, correlation between changes in expression of splicing factors and
specific splicing events for cell type or tissue was also detected using this technology
(Blanchette et al., 2005; Ule et al., 2005; Sugnet et al., 2006; Das et al., 2007; Fagnani
et al., 2007; Boutz et al., 2007; Hung et al., 2008) and for cancer (Relo´gio et al., 2005).
Standard gene microarrays have been also used to evaluate specific expression of splic-
ing factors in tissues (Yeo et al., 2004) and in cancer Kirschbaum-Slager et al. (2004).
Indeed, in the present work we showed how microarrays can be extensively used to sys-
tematically assess the expression levels of splicing regulators during cell differentiation, in
differentiated tissues and in cancer.
Although microarray technology has been revealed to be extremely useful for biological
research over the last two decades, hybridization-based approaches have some limitations:
detection is limited to RNA spliced patterns and genes previously identified; high back-
ground levels due to cross-hybridization; limited dynamic range of detection due to both
background and saturation of signals; comparison of expression levels across different ex-
periments is often difficult and requires complicated normalization methods (Wang et al.,
2008b).
Recently, the development of novel high-throughput DNA sequencing methods has
provided a new method for both mapping and quantifying transcriptomes, termed RNA-
Seq (RNA sequencing) (reviewed in Wang et al., 2008b).
Although more expensive and with some data analysis issues still to be solved, RNA-seq
can identify and quantify all transcript isoforms, allowing the discovery of novel splicing
patterns. The first studies with RNA-seq revealed that the number of genes alternatively
spliced was 92-95% (Wang et al., 2008a; Pan et al., 2008). Recently, studies using crosslink-
ing/immunoprecipitation followed by deep RNA sequencing (HITS-CLIP) generated RNA
maps for the splicing protein NOVA and FOX (Licatalosi et al., 2008; Yeo et al., 2009),
which can be used to predict the outcome of alternative splicing in other genes.
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Importantly, high-throughput technologies to address others layers of gene expres-
sion regulation are also emerging. Since changes in mRNA levels for transcript isoforms
and splicing factors may not necessarily reflect on protein levels and function, post-
transcriptional and post-translation regulation should also be considered in these genome-
wide studies. Despite the difficulty of assessing the impact of alternative splicing changes
in protein structure and function, differential display and sensitive mass-spectrometry
studies confirmed the detection of splice variants at the protein level in large scale (Tress
et al., 2008) and revealed regulatory circuits relevant to alternative splicing (Spellman
et al., 2007).
In conclusion, high-throughput technologies allowing genome-wide analyses are likely
to become standard tools for addressing functional, mechanistic, medical, or evolutionary
questions in gene function and alternative splicing. However, the most challenging goal for
the future will be to integrate the different layers of gene expression regulation to acquire
a systems biology view of the multiple molecular mechanisms that might be important for
cells, tissues and disease diagnosis and treatment. Therefore, future studies will require
the development of new computational approaches to explore large-scale data obtained by
the combinations of several technologies (e.g. cross-linking, immunoprecipitation, splicing-
sensitive microarrays, tiling microarray, RNA-seq and mass-spectrometry).
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Annex Tables
Annex tables are presented only on digital support (attached cd) and they are organized
according to chapters. The content of each each supplementary table is described below.
Tissue-specific splicing factor gene expression signatures
Annex Table A.1.1 Sequences of the primers used for qRT-PCR.
Annex Table A.1.2 Identification and description of the hybridizations analysed for
the differentiation processes.
Annex Table A.1.3 List of human splicing-related genes and respective murine ortho-
logues. The corresponding Affymetrix probes, Ensembl identifiers, protein family
and description are also indicated.
Annex Table A.1.4 Differentially expressed splicing-related genes at T1 and T2 differ-
entiation stages. Gene Expression fold-changes (log2) at T1 and T2 relative to T0
and respective B-statistics from Empirical Bayes are indicated. Statistical significant
fold-changes are highlighted in bold.
Annex Table A.1.5 Splicing-related gene signatures and respective log2 fold-changes
(differentiation process vs remaining processes).
Annex Table A.1.6 Identification and description of the hybridizations analysed for
adult tissues.
Annex Table A.1.7 List of differentially expressed genes found for each tissue. The
genes are identified with the name for Human and Mouse organisms and the fold-
changes are in log2 (tissue vs remaining tissues). References for previous studies
reporting association with splicing or tissue specificity are indicated.
Annex Table A.1.8 Tissue-specific expression signatures for splicing-related genes (hu-
man, chimpanzee and mouse microarray data). The genes are identified with the
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name for Human and Mouse organisms and the fold-changes are in log2 (tissue vs re-
maining tissues). References for previous studies reporting association with splicing
or tissue specificity are indicated.
Annex Table A.1.9 Tissue-specific expression signatures for splicing-related genes
(mouse microarray data). Microarray probes, gene name and respective fold-changes
in log2 (tissue vs remaining tissues) are indicated.
Cancer-specific misregulation of splicing factor gene expression
Annex Table A.2.1 List of human splicing-related genes and respective murine ortho-
logues. The corresponding Ensembl identifiers, protein family and description are
also indicated.
Annex Table A.2.2 Differentially expressed splicing-related genes comparing cancer
and corresponding normal tissue. Gene Expression fold-changes (log2) are indicated.
Cancer-associated splicing misregulation
Annex Table A.3.1 Genes with expression variation at gene level for colon cancer. The
fold-changes (log2) and B-values are indicated.
Annex Table A.3.2 Genes with expression variation at gene level for lung cancer. The
fold-changes (log2) and B-values are indicated.
Annex Table A.3.3 Genes with expression variation at exon level for colon cancer. The
fold-changes (log2) and B-values are indicated. The misspliced exon is identified
according to ExonMine and Ensembl databases. For each exon information is also
provided relative to presence in Ensembl transcripts, part of coding sequence (cds)
and of protein domain.
Annex Table A.3.4 Genes with expression variation at exon level for lung cancer. The
fold-changes (log2) and B-values are indicated. The misspliced exon is identified
according to ExonMine and Ensembl databases. For each exon information is also
provided relative to presence in Ensembl transcripts, part of coding sequence (cds)
and of protein domain.
Annex Table A.3.5 Biological functions associated with misregulated genes in colon
cancer. Top functions enriched for colon cancer using different gene sets split ac-
cording to misregulation level.
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Annex Table A.3.6 Biological functions associated with misregulated genes in lung can-
cer. Top functions enriched for lung cancer using different gene sets split according
to misregulation level.
Annex Table A.3.7 Biological pathways associated with misregulated genes in colon
cancer. Top pathways significantly impacted based on Pathway-Express (FDR adusted
p-value < 0.05) for colon cancer using different gene sets split according to misreg-
ulation level.
Annex Table A.3.8 Biological pathways associated with misregulated genes in lung can-
cer. Top pathways significantly impacted based on Pathway-Express (FDR adusted
p-value < 0.05) for lung cancer using different gene sets split according to misregu-
lation level.
Annex Table A.3.9 Misspliced genes in colon cancer containing CLIP-seq blocks for
SF2/ASF (SFRS1).
Annex Table A.3.10 Misspliced genes in lung cancer containing CLIP-seq blocks for
SF2/ASF (SFRS1).
Annex Table A.3.11 Motifs enriched in alternative slicing events for colon cancer.
Enriched motifs on each region of misspliced exons grouped with: exons enriched in
cancer samples (inclusion in cancer), exons enriched in normal samples (exclusion
in cancer), exons with splicing misregulated (inclusion or exclusion). P-value from
Fisher test applied in the comparison of frequencies for inclusion and exclusion events
is also indicated. Motifs that contained or were part of described motifs and could
resemble binding sites for splicing factors are identified.
Annex Table A.3.12 Motifs enriched in alternative slicing events for lung cancer. En-
riched motifs on each region of misspliced exons grouped with: exons enriched in
cancer samples (inclusion in cancer), exons enriched in normal samples (exclusion
in cancer), exons with splicing misregulated (inclusion or exclusion). P-value from
Fisher’s test applied in the comparison of frequencies for inclusion and exclusion
events is also indicated. Motifs that contained or were part of described motifs and
could resemble binding sites for splicing factors are identified.
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